```
* * * * * * * * * * *   Welcome to STN International   * * * * * * * * * * *

NEWS  1              Web Page URLs for STN Seminar Schedule - N. America
NEWS  2              "Ask CAS" for self-help around the clock
NEWS  3   May 10     PROUSDDR now available on STN
NEWS  4   May 19     PROUSDDR: One FREE connect hour, per account, in both May
                     and June 2004
NEWS  5   May 12     EXTEND option available in structure searching
NEWS  6   May 12     Polymer links for the POLYLINK command completed in REGISTRY
NEWS  7   May 17     FRFULL now available on STN
NEWS  8   May 27     New UPM (Update Code Maximum) field for more efficient patent
                     SDIs in CAplus
NEWS  9   May 27     CAplus super roles and document types searchable in REGISTRY
NEWS 10   May 27     Explore APOLLIT with free connect time in June 2004
NEWS 11   Jun 22     STN Patent Forums to be held July 19-22, 2004

NEWS EXPRESS  MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
              MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:29:11 ON 24 JUN 2004

=> file reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:29:19 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 JUN 2004  HIGHEST RN 698346-19-9
DICTIONARY FILE UPDATES:  23 JUN 2004  HIGHEST RN 698346-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.
```

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> file casreact

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.08	10.29

FILE 'CASREACT' ENTERED AT 09:43:31 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTENT:1840 - 20 Jun 2004 VOL 140 ISS 25

****
*
* CASREACT now has more than 8 million reactions
*
****

Some records from 1974 to 1991 are derived from the ZIC/VINITI data file and provided by InfoChem and some records are produced using some INPI data from the period prior to 1986.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Crossover limits have been increased. See HELP RNCROSSOVER for details.

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=>
L1 STRUCTURE UPLOADED

=> l1
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d l1
L1 HAS NO ANSWERS
L1 STR

=> s l1
SAMPLE SEARCH INITIATED 09:44:20 FILE 'CASREACT'
SCREENING COMPLETE - 6 REACTIONS TO VERIFY FROM 6 DOCUMENTS

100.0% DONE 6 VERIFIED 0 HIT RXNS 0 DOCS
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED VERIFICATIONS:          6 TO      266
PROJECTED ANSWERS:                0 TO        0

L2             0 SEA SSS SAM L1 (      0 REACTIONS)

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'CASREACT' IS 102.30 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 09:44:25 FILE 'CASREACT'
SCREENING COMPLETE -     389 REACTIONS TO VERIFY FROM     78 DOCUMENTS

100.0% DONE     389 VERIFIED        0 HIT RXNS                      0 DOCS
SEARCH TIME: 00.00.01

L3             0 SEA SSS FUL L1 (      0 REACTIONS)

=>
L4       STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4                STR

=> s l4
SAMPLE SEARCH INITIATED 09:45:43 FILE 'CASREACT'
SCREENING COMPLETE -       6 REACTIONS TO VERIFY FROM       6 DOCUMENTS

100.0% DONE       6 VERIFIED        0 HIT RXNS                      0 DOCS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED VERIFICATIONS:          6 TO      266
PROJECTED ANSWERS:                0 TO        0

L5             0 SEA SSS SAM L4 (      0 REACTIONS)

=> s l4 full
THE ESTIMATED SEARCH COST FOR FILE 'CASREACT' IS 102.30 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 09:45:48 FILE 'CASREACT'
SCREENING COMPLETE -     389 REACTIONS TO VERIFY FROM     78 DOCUMENTS

100.0% DONE     389 VERIFIED       89 HIT RXNS                      3 DOCS
SEARCH TIME: 00.00.01

L6             3 SEA SSS FUL L4 (     89 REACTIONS)

=> d l6, ibib abs crd, 1-3


L6   ANSWER 1 OF 3  CASREACT  COPYRIGHT 2004 ACS on STN
```

Full Text | Citing References

```
ACCESSION NUMBER:       139:301299  CASREACT
TITLE:                  Structure-Activity Relationships of the p38α MAP
                        Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-
                        3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph-
```

thalen-1-yl]urea (BIRB 796)

AUTHOR(S): Regan, John; Capolino, Alison; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Hickey, Eugene; Kroe, Rachel R.; Madwed, Jeffrey; Moriak, Monica; Nelson, Richard; Pargellis, Christopher A.; Swinamer, Alan; Torcellini, Carol; Tsang, Michele; Moss, Neil

CORPORATE SOURCE: Department of Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals Research and Development Center, Ridgefield, CT, 06877, USA

SOURCE: Journal of Medicinal Chemistry (2003), 46(22), 4676-4686
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We report on the structure-activity relationships (SAR) of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796), an inhibitor of p38α MAP kinase which has advanced into human clin. trials for the treatment of autoimmune diseases. Thermal denaturation was used to establish mol. binding affinities for this class of p38α inhibitors. The tert-Bu group remains a crit. binding element by occupying a lipophilic domain in the kinase which is exposed upon rearrangement of the activation loop. An arom. ring attached to N-2 of the pyrazole nucleus provides important π-CH2 interactions with the kinase. The role of groups attached through an ethoxy group to the 4-position of the naphthalene and directed into the ATP-binding domain is elucidated. Pharmacophores with good hydrogen bonding potential, such as morpholine, pyridine, and imidazole, shift the melting temp. of p38α by 16-17° translating into Kd values of 50-100 pM. Finally, we describe several compds. that potently inhibit TNF-α prodn. when dosed orally in mice.

RX(33) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(34) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(35) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(36) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(37) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(55) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(56) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(57) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(60) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(62) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(63) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(64) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(66) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(76) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(85) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(86) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(87) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(89) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(90) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(91) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(93) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(94) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(95) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(98) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(99) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(100) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(101) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(102) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(111) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(116) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(117) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(118) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(119) OF 120 - REACTION DIAGRAM NOT AVAILABLE

RX(120) OF 120 - REACTION DIAGRAM NOT AVAILABLE

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CASREACT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 138:24709 CASREACT

TITLE: Preparation of pyrazole compds. and bis pyrazole-1H-pyrazole intermediates as antiinflammatory agents

INVENTOR(S): Kapadia, Suresh R.; Song, Jinhua J.; Yee, Nathan K.

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: U.S., 37 pp., Cont.-in-part of U.S. 6,372,773.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6492529	B1	20021210	US 2002-67492	20020205

US 6319921	B1	20011120	US 2000-484638	20000118
US 6333325	B1	20011225	US 2001-871559	20010531
US 6329415	B1	20011211	US 2001-891579	20010626
US 2002065285	A1	20020530	US 2001-891820	20010626
US 6506748	B2	20030114		
US 6372773	B1	20020416	US 2001-920899	20010802
PRIORITY APPLN. INFO.:			US 2000-484638	20000118
			US 2001-920899	20010802
			US 1999-116400P	19990119
			US 2001-891579	20010626

OTHER SOURCE(S): MARPAT 138:24709
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrazole compds., e.g. I, as well as bis pyrazole-1H-pyrazole intermediate compds. e.g. II, were prepd. The compds. are useful in pharmaceutic compns. for treating diseases or pathol. conditions involving inflammation such as chronic inflammatory diseases. All prepd. compds. had IC50 < 10 mM for inhibition of TNF.alpha. in lipopolysaccharide stimulated THP cells.

RX(74) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(79) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(82) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(84) OF 282 - 2 STEPS



RX(84) OF 282 - 2 STEPS



RX(93) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(95) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(96) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(97) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(98) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(105) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(134) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(136) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(141) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(143) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(145) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(147) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(148) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(149) OF 282 - 3 STEPS



RX(149) OF 282 - 3 STEPS



RX(151) OF 282 - 3 STEPS



+



(step 2)

1. HCl, Dioxane
2. EtN(Pr-i)2, DMSO
3. NaI, Me2CO

RX(151) OF 282 - 3 STEPS

RX(152) OF 282 - 4 STEPS



+



(step 3)

1. BrCH2CH2Cl, K2CO3, MeCN
2. HCl, Dioxane
3. EtN(Pr-i)2, DMSO
4. NaI, Me2CO

RX(152) OF 282 - 4 STEPS



RX(155) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(156) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(164) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(166) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(167) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(168) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(169) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(170) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(175) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(176) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(177) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(178) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(179) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(180) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(181) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(192) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(194) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(230) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(231) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(234) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(235) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(238) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(239) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(243) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(244) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(245) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(246) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(247) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(251) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(252) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(253) OF 282 - REACTION DIAGRAM NOT AVAILABLE

RX(254) OF 282 - REACTION DIAGRAM NOT AVAILABLE
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 CASREACT COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 137:119059 CASREACT
TITLE: Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
AUTHOR(S): Regan, John; Breitfelder, Steffen; Cirillo, Pier; Gilmore, Thomas; Graham, Anne G.; Hickey, Eugene; Klaus, Bernhard; Madwed, Jeffrey; Moriak, Monica; Moss, Neil; Pargellis, Chris; Pav, Sue; Proto, Alfred; Swinamer, Alan; Tong, Liang; Torcellini, Carol
CORPORATE SOURCE: Research and Development Center, Department of Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, 06877, USA
SOURCE: Journal of Medicinal Chemistry (2002), 45(14), 2994-3008
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We report on a series of N-pyrazole, N'-aryl ureas and their mode of binding to p38 mitogen activated protein kinase. Importantly, a key binding domain that is distinct from the ATP (ATP) binding site is exposed when the conserved activation loop, consisting in part of Asp168-Phe169-Gly170, adopts a conformation permitting lipophilic and hydrogen bonding interactions between this class of inhibitors and the protein. We describe the correlation of the structure-activity relationships and crystallog. structures of these inhibitors with p38. In addn., we incorporated another binding pharmacophore that forms a hydrogen bond at the ATP binding site. This modification affords significant improvements in binding, cellular, and in vivo potencies resulting in the selection of Compd. 45 (BIRB 796) as a clin. candidate for the treatment of inflammatory diseases.

RX(67) OF 99 - REACTION DIAGRAM NOT AVAILABLE

RX(86) OF 99 - REACTION DIAGRAM NOT AVAILABLE

RX(88) OF 99 - REACTION DIAGRAM NOT AVAILABLE
REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	217.25	227.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.98	-1.98

FILE 'REGISTRY' ENTERED AT 09:47:01 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2004 HIGHEST RN 698346-19-9
DICTIONARY FILE UPDATES: 23 JUN 2004 HIGHEST RN 698346-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L7 STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7 STR



Page 1-A

0 42 S 43





Page 1-C







Page 1-D

Page 1-E



PRO

Page 2-C





Page 2-D



Page 3-C



Page 3-D
VAR G1=42/43
VAR G2=5/10/15/20/25/30/35
NODE ATTRIBUTES:
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS R AT 6
NSPEC IS R AT 7
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 10

```
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS R      AT  14
NSPEC   IS R      AT  15
NSPEC   IS R      AT  16
NSPEC   IS R      AT  17
NSPEC   IS R      AT  18
NSPEC   IS R      AT  19
NSPEC   IS R      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS R      AT  24
NSPEC   IS R      AT  25
NSPEC   IS R      AT  26
NSPEC   IS R      AT  27
NSPEC   IS R      AT  28
NSPEC   IS R      AT  29
NSPEC   IS R      AT  30
NSPEC   IS R      AT  31
NSPEC   IS R      AT  32
NSPEC   IS R      AT  33
NSPEC   IS R      AT  34
NSPEC   IS R      AT  35
NSPEC   IS C      AT  36
NSPEC   IS C      AT  37
NSPEC   IS C      AT  38
NSPEC   IS C      AT  39
NSPEC   IS C      AT  40
NSPEC   IS C      AT  41
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  36 37 38 42 43
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  43

STEREO ATTRIBUTES: NONE


=> file reg
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                0.84     228.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                0.00      -1.98

FILE 'REGISTRY' ENTERED AT 09:48:17 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 JUN 2004  HIGHEST RN 698346-19-9
```

```
DICTIONARY FILE UPDATES:  23 JUN 2004  HIGHEST RN 698346-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d his

     (FILE 'HOME' ENTERED AT 09:29:11 ON 24 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 09:29:19 ON 24 JUN 2004

     FILE 'CASREACT' ENTERED AT 09:43:31 ON 24 JUN 2004
L1                STRUCTURE UPLOADED
L2              0 S L1
L3              0 S L1 FULL
L4                STRUCTURE UPLOADED
L5              0 S L4
L6              3 S L4 FULL

     FILE 'REGISTRY' ENTERED AT 09:47:01 ON 24 JUN 2004
L7                STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 09:48:17 ON 24 JUN 2004

=> s l7/prep
QUALIFICATION NOT VALID FOR L7
Field code qualifications can only be applied to text
terms.

=> s l7
SAMPLE SEARCH INITIATED 09:48:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    763 TO ITERATE

100.0% PROCESSED     763 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         13603 TO    16917
PROJECTED ANSWERS:             1081 TO     2159

L8            50 SEA SSS SAM L7

=> s l7 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 09:48:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  15438 TO ITERATE

100.0% PROCESSED   15438 ITERATIONS                            1575 ANSWERS
```

```
SEARCH TIME: 00.00.01

L9          1575 SEA SSS FUL L7

=> file hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       155.42     383.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -1.98

FILE 'HCAPLUS' ENTERED AT 09:48:40 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 24 Jun 2004  VOL 140 ISS 26
FILE LAST UPDATED: 23 Jun 2004  (20040623/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> s l9/prep
           312 L9
       3163220 PREP/RL
L10         225 L9/PREP
                  (L9 (L) PREP/RL)

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         2.36     386.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -1.98

FILE 'REGISTRY' ENTERED AT 09:48:47 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 JUN 2004  HIGHEST RN 698346-19-9
```

DICTIONARY FILE UPDATES: 23 JUN 2004 HIGHEST RN 698346-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L11 STRUCTURE UPLOADED

=> d l11
L11 HAS NO ANSWERS
L11 STR



Page 1-A





Page 1-C







Page 1-D

Page 1-E





Page 2-C

Page 3-C

VAR G2=5/10/15/20/25/30/35

NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS R	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20

```
NSPEC    IS R      AT  21
NSPEC    IS R      AT  22
NSPEC    IS R      AT  23
NSPEC    IS R      AT  24
NSPEC    IS R      AT  25
NSPEC    IS R      AT  26
NSPEC    IS R      AT  27
NSPEC    IS R      AT  28
NSPEC    IS R      AT  29
NSPEC    IS R      AT  30
NSPEC    IS R      AT  31
NSPEC    IS R      AT  32
NSPEC    IS R      AT  33
NSPEC    IS R      AT  34
NSPEC    IS R      AT  35
NSPEC    IS C      AT  36
NSPEC    IS C      AT  37
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  37
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  37

STEREO ATTRIBUTES: NONE


=> s l11
SAMPLE SEARCH INITIATED 09:51:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  28473 TO ITERATE

  3.5% PROCESSED    1000 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       559379 TO   579541
PROJECTED ANSWERS:          117185 TO   126543

L12           50 SEA SSS SAM L11

=>
L13      STRUCTURE UPLOADED

=> d l13
L13 HAS NO ANSWERS
L13                 STR
```




```
Page 1-A
```





Page 1-C







Page 1-D



Page 1-E





Page 2-C



Page 3-C



Page 3-D

```
VAR G2=5/10/15/20/25/30/35
NODE ATTRIBUTES:
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS R      AT   6
NSPEC   IS R      AT   7
NSPEC   IS R      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS R      AT  14
NSPEC   IS R      AT  15
NSPEC   IS R      AT  16
NSPEC   IS R      AT  17
NSPEC   IS R      AT  18
NSPEC   IS R      AT  19
NSPEC   IS R      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS R      AT  24
NSPEC   IS R      AT  25
NSPEC   IS R      AT  26
NSPEC   IS R      AT  27
NSPEC   IS R      AT  28
NSPEC   IS R      AT  29
NSPEC   IS R      AT  30
NSPEC   IS R      AT  31
NSPEC   IS R      AT  32
NSPEC   IS R      AT  33
NSPEC   IS R      AT  34
NSPEC   IS R      AT  35
NSPEC   IS C      AT  36
NSPEC   IS C      AT  37
NSPEC   IS C      AT  38
NSPEC   IS C      AT  39
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  37 38 39
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  39

STEREO ATTRIBUTES: NONE


=> s l13
SAMPLE SEARCH INITIATED 09:51:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  28473 TO ITERATE

  3.5% PROCESSED    1000 ITERATIONS                          49 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      559379 TO   579541
PROJECTED ANSWERS:          25663 TO    30143

L14           49 SEA SSS SAM L13

=>
L15      STRUCTURE UPLOADED

=> d l15
L15 HAS NO ANSWERS
L15                STR
```



Page 1-A






3
13
N
C
14
12
C
45 A
15
11
N
M1
A 44
47 A
18
C
N
19
17
C
20
16
N
M1
46 A
48 A
23
C
N
22
N
21
N
M1
Page 1-C
Page 1-D
24
C
25
Page 1-E
A 49
6
M1
33
N
C
34
32
N
C
35
31
N
M1
Page 2-C



Page 3-C



Page 3-D

VAR G2=5/10/15/20/25/30/35

NODE ATTRIBUTES:

HCOUNT	IS	M1	AT	1
HCOUNT	IS	M1	AT	6
HCOUNT	IS	M1	AT	11
HCOUNT	IS	M1	AT	16
HCOUNT	IS	M1	AT	21
HCOUNT	IS	M1	AT	26
HCOUNT	IS	M1	AT	31
NSPEC	IS	R	AT	1
NSPEC	IS	R	AT	2
NSPEC	IS	R	AT	3
NSPEC	IS	R	AT	4
NSPEC	IS	R	AT	5
NSPEC	IS	R	AT	6
NSPEC	IS	R	AT	7
NSPEC	IS	R	AT	8
NSPEC	IS	R	AT	9
NSPEC	IS	R	AT	10
NSPEC	IS	R	AT	11
NSPEC	IS	R	AT	12
NSPEC	IS	R	AT	13
NSPEC	IS	R	AT	14
NSPEC	IS	R	AT	15
NSPEC	IS	R	AT	16
NSPEC	IS	R	AT	17
NSPEC	IS	R	AT	18
NSPEC	IS	R	AT	19
NSPEC	IS	R	AT	20
NSPEC	IS	R	AT	21
NSPEC	IS	R	AT	22
NSPEC	IS	R	AT	23
NSPEC	IS	R	AT	24
NSPEC	IS	R	AT	25
NSPEC	IS	R	AT	26
NSPEC	IS	R	AT	27
NSPEC	IS	R	AT	28
NSPEC	IS	R	AT	29
NSPEC	IS	R	AT	30
NSPEC	IS	R	AT	31

```
NSPEC    IS R      AT  32
NSPEC    IS R      AT  33
NSPEC    IS R      AT  34
NSPEC    IS R      AT  35
NSPEC    IS C      AT  36
NSPEC    IS C      AT  37
NSPEC    IS C      AT  38
NSPEC    IS C      AT  39
NSPEC    IS RC     AT  40
NSPEC    IS RC     AT  41
NSPEC    IS RC     AT  42
NSPEC    IS RC     AT  43
NSPEC    IS RC     AT  44
NSPEC    IS RC     AT  45
NSPEC    IS RC     AT  46
NSPEC    IS RC     AT  47
NSPEC    IS RC     AT  48
NSPEC    IS RC     AT  49
DEFAULT MLEVEL IS ATOM
MLEVEL   IS CLASS  AT  37 38 39 40 41 42 43 44 45 46 47 48 49
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  49

STEREO ATTRIBUTES: NONE


=> s l15
SAMPLE SEARCH INITIATED 09:55:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  28473 TO ITERATE

  3.5% PROCESSED    1000 ITERATIONS                                  8 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       559379 TO   579541
PROJECTED ANSWERS:            3650 TO     5460

L16             8 SEA SSS SAM L15

=>
L17      STRUCTURE UPLOADED

=> d l17
L17 HAS NO ANSWERS
L17                 STR
 0 7  S 8
```

6 C



Page 1-B

```
VAR G1=7/8
NODE ATTRIBUTES:
HCOUNT   IS M1      AT   4
NSPEC    IS C       AT   1
NSPEC    IS C       AT   2
NSPEC    IS C       AT   3
NSPEC    IS C       AT   4
NSPEC    IS C       AT   5
NSPEC    IS RC      AT   6
DEFAULT MLEVEL IS ATOM
MLEVEL   IS CLASS   AT   2  4  6  7  8
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE


=> s l17
SAMPLE SEARCH INITIATED 10:01:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  53469 TO ITERATE

  1.9% PROCESSED    1000 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      EXCEEDS 1000000
PROJECTED ANSWERS:         EXCEEDS  143477

L18           50 SEA SSS SAM L17

=> e indanyl/cn
E1            1      INDANTRIONE/CN
E2            1      INDANTRIONE HYDRATE/CN
E3            0 --> INDANYL/CN
E4            1      INDANYL (4-(4-(PIPERIDINYL)BUT-1-YNYL)BENZYL)AMINE/CN
E5            1      INDANYL CARBENICILLIN/CN
E6            1      INDANYL CARBENICILLIN SODIUM SALT/CN
E7            1      INDANYL MESYLATE/CN
```

```
E8              1      INDANYLIUM, 2-((3-ETHOXY-5-METHOXYINDEN-2-YL)METHYLENE)-1-HY
                       DROXY-6-METHOXY-/CN
E9              1      INDANYLPHENOL/CN
E10             1      INDAPAMIDE/CN
E11             1      INDAQUASSIN A/CN
E12             1      INDAQUASSIN B/CN

=> s e7
L19             1 "INDANYL MESYLATE"/CN

=> d l19

L19  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   777-72-0  REGISTRY
CN   1H-Inden-2-ol, 2,3-dihydro-, methanesulfonate (9CI)   (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   2-Indanol, methanesulfonate (7CI, 8CI)
OTHER NAMES:
CN   2-Indanyl methanesulfonate
CN   Indanyl mesylate
CN   NSC 80565
FS   3D CONCORD
MF   C10 H12 O3 S
LC   STN Files:   BEILSTEIN*, CA, CAOLD, CAPLUS, PS, TOXCENTER, USPATFULL
         (*File contains numerically searchable property data)
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  PREP (Preparation); RACT (Reactant or reagent)
RL.NP  Roles from non-patents:  PREP (Preparation); RACT (Reactant or reagent);
       NORL (No role in record)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

                10 REFERENCES IN FILE CA (1907 TO DATE)
                10 REFERENCES IN FILE CAPLUS (1907 TO DATE)
                 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> e benzofuran/cn
E1              1      BENZOFUR GG/CN
E2              1      BENZOFUR P/CN
E3              1 --> BENZOFURAN/CN
E4              1      BENZOFURAN POLYMER/CN
E5              1      BENZOFURAN RADICAL CATION/CN
E6              1      BENZOFURAN, ((2,4-DICHLOROPHENOXY)METHYL)-/CN
E7              1      BENZOFURAN, (2-PROPENYL)-/CN
E8              1      BENZOFURAN, 2(OR 3)-METHYL-/CN
E9              1      BENZOFURAN, 2,-BIS((P-AMINOPHENYL)ACETYL)-6-METHOXY-/CN
E10             1      BENZOFURAN, 2,2',2'',2'''-(3,6-DIMETHYL-1,2,4,5-BENZENETETRA
                       YL)TETRAKIS-/CN
E11             1      BENZOFURAN, 2,2',2'',2'''-(9,9'-SPIROBI(9H-FLUOREN)-2,2',7,7
                       '-TETRAYL)TETRAKIS-/CN
E12             1      BENZOFURAN, 2,2',2'',2'''-(METHANETETRAYLTETRA-4,1-PHENYLENE
                       )TETRAKIS-/CN
```

```
=> s e3
L20             1 BENZOFURAN/CN

=> d 120

L20  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   271-89-6  REGISTRY
CN   Benzofuran (6CI, 8CI, 9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1-Oxindene
CN   2,3-Benzofuran
CN   AT 33852
CN   Benzofurfuran
CN   Benzo[b]furan
CN   Coumarone
CN   NSC 1255
CN   R 7204
FS   3D CONCORD
MF   C8 H6 O
CI   COM, RPS
LC   STN Files:   AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
       CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DETHERM*, EMBASE, ENCOMPLIT,
       ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB,
       IFIPAT, IFIUDB, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA,
       PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2,
       USPATFULL, VTB
         (*File contains numerically searchable property data)
     Other Sources:   DSL**, EINECS**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA  CAplus document type:  Book; Conference; Dissertation; Journal; Patent;
       Preprint; Report
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological study);
       FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
       (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
       (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P  Roles for non-specific derivatives from patents:  ANST (Analytical
       study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation);
       PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES
       (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
       (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
       (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents:  ANST (Analytical
       study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC
       (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process);
       PRP (Properties); RACT (Reactant or reagent); USES (Uses)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

            1993 REFERENCES IN FILE CA (1907 TO DATE)
             263 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
```

```
            1993 REFERENCES IN FILE CAPLUS (1907 TO DATE)
              59 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> e indenyl/cn
E1            1      INDENOPYRENE, METHYL-/CN
E2            1      INDENOPYRENONE/CN
E3            1 --> INDENYL/CN
E4            1      INDENYL ANION/CN
E5            1      INDENYL POTASSIUM/CN
E6            1      INDENYL ZIRCONIUM TRIS(DIETHYLCARBAMATE)/CN
E7            1      INDENYL ZIRCONIUM TRIS(TRIMETHYLACETATE)/CN
E8            1      INDENYL(TRI(TERT-BUTYL)PHOSPHINIMIDO)TITANIUM DICHLORIDE/CN
E9            1      INDENYL, 1,2,3,4,5,6,7-HEPTACHLORO-/CN
E10           1      INDENYL, 1-DIOXY-/CN
E11           1      INDENYL, 2-METHYL-/CN
E12           1      INDENYL, 5-HYDROXY-/CN

=> s e3
L21           1 INDENYL/CN

=> d l21

L21  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   71551-80-9  REGISTRY
CN   Indenyl (7CI, 9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Inden-2-yl
DR   2143-54-6, 117988-54-2
MF   C9 H7
CI   MAN
LC   STN Files:   BIOSIS, CA, CAOLD, CAPLUS, TOXCENTER
DT.CA  CAplus document type:  Dissertation; Journal
RL.NP  Roles from non-patents:  FORM (Formation, nonpreparative); OCCU
       (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
       (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents:  PREP
       (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
       reagent)

 STRUCTURE DIAGRAM IS NOT AVAILABLE
              24 REFERENCES IN FILE CA (1907 TO DATE)
               4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
              24 REFERENCES IN FILE CAPLUS (1907 TO DATE)
               2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


=>
L22      STRUCTURE UPLOADED

=> d l22
L22 HAS NO ANSWERS
L22                STR
```

0 23 S 24

Page 1-A

Page 1-B

Page 2-B



Page 3-B

20

21

Page 3-C

VAR G1=23/24

VAR G2=7/20

NODE ATTRIBUTES:

HCOUNT IS M1 AT 4
NSPEC IS C AT 1
NSPEC IS C AT 2
NSPEC IS C AT 3
NSPEC IS C AT 4
NSPEC IS RC AT 5
NSPEC IS C AT 6
NSPEC IS R AT 7
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 10
NSPEC IS R AT 11
NSPEC IS R AT 12
NSPEC IS R AT 13
NSPEC IS R AT 14
NSPEC IS R AT 15
NSPEC IS R AT 16
NSPEC IS R AT 17
NSPEC IS R AT 18
NSPEC IS R AT 19
NSPEC IS R AT 20
NSPEC IS R AT 21
NSPEC IS R AT 22
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 2 4 5 23 24
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

=> s 122
SAMPLE SEARCH INITIATED 10:10:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12830 TO ITERATE

```
  7.8% PROCESSED    1000 ITERATIONS                                  50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:       249817 TO   263383
PROJECTED ANSWERS:           62503 TO    69389

L23           50 SEA SSS SAM L22

=> s l22 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:10:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 259836 TO ITERATE

100.0% PROCESSED  259836 ITERATIONS                          65845 ANSWERS
SEARCH TIME: 00.00.02

L24        65845 SEA SSS FUL L22

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               189.14     575.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                0.00      -1.98

FILE 'HCAPLUS' ENTERED AT 10:10:57 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 24 Jun 2004  VOL 140 ISS 26
FILE LAST UPDATED: 23 Jun 2004  (20040623/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> s l24/rct
         26409 L24
       2633407 RCT/RL
L25       6528 L24/RCT
                (L24 (L) RCT/RL)
```

```
=> d his

     (FILE 'HOME' ENTERED AT 09:29:11 ON 24 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 09:29:19 ON 24 JUN 2004

     FILE 'CASREACT' ENTERED AT 09:43:31 ON 24 JUN 2004
L1                STRUCTURE UPLOADED
L2              0 S L1
L3              0 S L1 FULL
L4                STRUCTURE UPLOADED
L5              0 S L4
L6              3 S L4 FULL

     FILE 'REGISTRY' ENTERED AT 09:47:01 ON 24 JUN 2004
L7                STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 09:48:17 ON 24 JUN 2004
L8             50 S L7
L9           1575 S L7 FULL

     FILE 'HCAPLUS' ENTERED AT 09:48:40 ON 24 JUN 2004
L10           225 S L9/PREP

     FILE 'REGISTRY' ENTERED AT 09:48:47 ON 24 JUN 2004
L11               STRUCTURE UPLOADED
L12            50 S L11
L13               STRUCTURE UPLOADED
L14            49 S L13
L15               STRUCTURE UPLOADED
L16             8 S L15
L17               STRUCTURE UPLOADED
L18            50 S L17
                  E INDANYL/CN
L19             1 S E7
                  E BENZOFURAN/CN
L20             1 S E3
                  E INDENYL/CN
L21             1 S E3
L22               STRUCTURE UPLOADED
L23            50 S L22
L24         65845 S L22 FULL

     FILE 'HCAPLUS' ENTERED AT 10:10:57 ON 24 JUN 2004
L25          6528 S L24/RCT

=> s l25 and l10
L26            21 L25 AND L10

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     9.44     584.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.98

FILE 'REGISTRY' ENTERED AT 10:13:07 ON 24 JUN 2004
```

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2004 HIGHEST RN 698346-19-9
DICTIONARY FILE UPDATES: 23 JUN 2004 HIGHEST RN 698346-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L27 STRUCTURE UPLOADED

=> d l27
L27 HAS NO ANSWERS
L27 STR

C 7 N 8
Page 1-A



Page 1-B
VAR G1=7/8
NODE ATTRIBUTES:
HCOUNT IS M1 AT 1
HCOUNT IS M2 AT 6
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS C AT 6
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 6
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE

```
=> s l27
SAMPLE SEARCH INITIATED 10:13:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 244417 TO ITERATE

  0.4% PROCESSED    1000 ITERATIONS                                 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **INCOMPLETE**
                        BATCH    **INCOMPLETE**
PROJECTED ITERATIONS:      EXCEEDS 1000000
PROJECTED ANSWERS:         EXCEEDS  329523

L28           50 SEA SSS SAM L27

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    0.42      585.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                    0.00       -1.98

FILE 'HCAPLUS' ENTERED AT 10:13:28 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 24 Jun 2004  VOL 140 ISS 26
FILE LAST UPDATED: 23 Jun 2004   (20040623/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> d his

     (FILE 'HOME' ENTERED AT 09:29:11 ON 24 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 09:29:19 ON 24 JUN 2004

     FILE 'CASREACT' ENTERED AT 09:43:31 ON 24 JUN 2004
L1                STRUCTURE UPLOADED
L2              0 S L1
L3              0 S L1 FULL
L4                STRUCTURE UPLOADED
```

```
L5              0 S L4
L6              3 S L4 FULL

     FILE 'REGISTRY' ENTERED AT 09:47:01 ON 24 JUN 2004
L7                STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 09:48:17 ON 24 JUN 2004
L8             50 S L7
L9           1575 S L7 FULL

     FILE 'HCAPLUS' ENTERED AT 09:48:40 ON 24 JUN 2004
L10           225 S L9/PREP

     FILE 'REGISTRY' ENTERED AT 09:48:47 ON 24 JUN 2004
L11               STRUCTURE UPLOADED
L12            50 S L11
L13               STRUCTURE UPLOADED
L14            49 S L13
L15               STRUCTURE UPLOADED
L16             8 S L15
L17               STRUCTURE UPLOADED
L18            50 S L17
                  E INDANYL/CN
L19             1 S E7
                  E BENZOFURAN/CN
L20             1 S E3
                  E INDENYL/CN
L21             1 S E3
L22               STRUCTURE UPLOADED
L23            50 S L22
L24         65845 S L22 FULL

     FILE 'HCAPLUS' ENTERED AT 10:10:57 ON 24 JUN 2004
L25          6528 S L24/RCT
L26            21 S L25 AND L10

     FILE 'REGISTRY' ENTERED AT 10:13:07 ON 24 JUN 2004
L27               STRUCTURE UPLOADED
L28            50 S L27

     FILE 'HCAPLUS' ENTERED AT 10:13:28 ON 24 JUN 2004

=> s l26 and tan, z?/au
           1089 TAN, Z?/AU
L29           0 L26 AND TAN, Z?/AU

=> s l26 and song, j?/au
           4843 SONG, J?/AU
L30           0 L26 AND SONG, J?/AU

=> d l26, ibib abs hitstr, 1-21

L26  ANSWER 1 OF 21  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

Full Text | Citing References

```
ACCESSION NUMBER:          2004:60480  HCAPLUS
DOCUMENT NUMBER:           140:111415
TITLE:                     Preparation of imidazole derivatives as chymase
                           inhibitors
INVENTOR(S):               Kitano, Masafumi; Yamaguchi, Hiroki
```

PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007464	A1	20040122	WO 2003-JP8682	20030708

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-201739 A 20020710
OTHER SOURCE(S): MARPAT 140:111415
GI



AB The title compds. I [wherein X1 = (un)substituted alkylene; X2 and Q = independently a single bond or (un)substituted alkylene; Y1 = (hetero)cyclylene; Y2 = (hetero)cyclyl; M = (un)substituted CO2H, SO3H, CONH2, SO2NH2, -NHSO2H, or tetrazolyl, etc.; R1 and R2 = independently (hetero)cyclyl, H, halo, NO2, CN, CO2H, (un)substituted alkyl, alkenyl, alkynyl, alkoxycarbonyl, acyl, OH, NH2, CONH2, SO2NH2, SH, SOH, or SO2H, etc.] or prodrugs, or pharmaceutically acceptable salts thereof are prepd. For example, the compd. II was prepd. in a multi-step synthesis. II showed inhibitory activity with IC50 of 0.026 μM against human chymase. I have chymase inhibitory activity, and are useful as a therapeutic agent for hypertension, cardiac failure, etc. (no data).

IT **647850-05-3P 647850-07-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(drug candidate; prepn. of imidazole derivs. as chymase inhibitors)

RN 647850-05-3 HCAPLUS
CN Benzoic acid, 2-[[[[1-(1-naphthalenylmethyl)-1H-imidazol-2-yl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 647850-07-5 HCAPLUS
CN Benzoic acid, 2-[[[methyl[1-(1-naphthalenylmethyl)-1H-imidazol-2-yl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT **259537-23-0P 439142-85-5P 647850-99-5P**
647851-03-4P
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; RACT (Reactant or reagent)
(intermediate; prepn. of imidazole derivs. as chymase inhibitors)

RN 259537-23-0 HCAPLUS
CN Benzoic acid, 2-[(phenoxycarbonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 439142-85-5 HCAPLUS
CN Carbamic acid, [2-(4-morpholinylcarbonyl)phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 647850-99-5 HCAPLUS
CN Morpholine, 4-[2-[[[[1-(1-naphthalenylmethyl)-1H-imidazol-2-yl]amino]carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 647851-03-4 HCAPLUS
CN Benzoic acid, 2-[[[methyl[1-(1-naphthalenylmethyl)-1H-imidazol-2-yl]amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:41269 HCAPLUS
DOCUMENT NUMBER: 140:77038
TITLE: Preparation of 3-[heteroarylmethoxy]pyridines and their analogues as p38 map kinase inhibitors
INVENTOR(S): Murray, Christopher William; Hartshorn, Michael John; Frederickson, Martyn; Congreve, Miles Stuart; Padova, Alessandro; Woodhead, Steven John; Gill, Adrian Liam; Woodhead, Andrew James
PATENT ASSIGNEE(S): Astex Technology Limited, UK
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004720	A1	20040115	WO 2003-GB2864	20030703

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

GB 2002-15383	A	20020703
US 2002-393121P	P	20020703
GB 2002-26149	A	20021108

OTHER SOURCE(S): MARPAT 140:77038

GI



I

AB Title compds. I [X=Y = CR2=CR3, CR2=N; R1 = H, halo, amino, etc.; R2-3 = H, alkyl, aryl, etc.; R4 = carboaryl, heteroaryl; R5 = halo, amino, carboxamido, etc.] are prepd. For instance, 2-amino-3-benzyloxypyridine is prepd. by alkylation of 2-amino-3-hydroxypyridine with benzyl chloride. A related example, 2-amino-3-[2-phenylbenzyloxy]pyridine has IC50 < 10μM for p38 map kinase. I are useful in the treatment of diseases ameliorated by inhibiting p38 MAP kinase.

IT **642084-55-7P**, 2-[2-Fluoro-5-[[[[1-(tert-butyl)-3-phenylpyrazol-5-yl]amino]carbonyl]amino]benzyloxy]pyrazine **642085-05-0P**, N-(5-(tert-Butyl)-2-phenyl-2H-pyrazol-3-yl)-N'-[4-chloro-3-(((pyridin-3-yl)oxy)methyl)phenyl]urea **642085-37-8P**, N-(5-tert-Butyl-2-phenyl-2H-pyrazol-3-yl)-N'-[4-fluoro-3-(((pyrazin-2-yl)oxy)methyl)phenyl]urea **642085-49-2P**, N-[5-tert-Butyl-2-(2,4-difluorophenyl)-2H-pyrazol-3-yl]-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-50-5P**, N-[5-tert-Butyl-2-(4-chlorophenyl)-2H-pyrazol-3-yl]-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-51-6P**, N-[5-(4-Chlorophenyl)-2-phenyl-2H-pyrazol-3-yl]-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-52-7P**, N-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-53-8P**, N-[5-(4-Chlorophenyl)-2-(4-fluorophenyl)-2H-pyrazol-3-yl]-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-54-9P**, N-(2,5-Diphenyl-2H-pyrazol-3-yl)-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-56-1P**, N-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-yl)-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-57-2P**, N-(2-(Benzothiazol-2-yl)-5-(tert-butyl)-2H-pyrazol-3-yl)-N'-[4-fluoro-3-(((pyrazin-2-yl)oxy)methyl)phenyl]urea **642085-58-3P**, N-[5-tert-Butyl-2-(6-chloropyridazin-3-yl)-2H-pyrazol-3-yl]-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-59-4P**, N-[5-tert-Butyl-2-(2,6-dimethylpyrimidin-4-yl)-2H-pyrazol-3-yl]-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-61-8P**, N-(5-(tert-Butyl)-2-(pyridin-4-yl)-2H-pyrazol-3-yl)-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-62-9P**, N-[2-(4-Fluorophenyl)-5-(tetrahydrofuran-2-yl)-2H-pyrazol-3-yl]-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-63-0P**, N-[5-(tert-Butyl)-2-(4-(methanesulfonyl)phenyl)-2H-pyrazol-3-yl]-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-64-1P**, N-[2-(4-tert-Butylphenyl)-5-cyclopropyl-2H-pyrazol-3-yl]-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea **642085-65-2P**, N-[2-(4-Fluorophenyl)-5-(tetrahydropyran-4-yl)-2H-pyrazol-3-yl]-N'-[4-fluoro-3-(pyrazin-2-yloxymethyl)phenyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**;

USES (Uses)
(prepn. of 3-[heteroarylmethoxy]pyridines and their analogs as p38 map kinase inhibitors for treatment of arthritis)

RN 642084-55-7 HCAPLUS
CN Urea, N-[1-(1,1-dimethylethyl)-3-phenyl-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-05-0 HCAPLUS
CN Urea, N-[4-chloro-3-[(3-pyridinyloxy)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-phenyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 642085-37-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-phenyl-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-49-2 HCAPLUS
CN Urea, N-[1-(2,4-difluorophenyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-50-5 HCAPLUS
CN Urea, N-[1-(4-chlorophenyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-51-6 HCAPLUS
CN Urea, N-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-52-7 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-53-8 HCAPLUS
CN Urea, N-[3-(4-chlorophenyl)-1-(4-fluorophenyl)-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-54-9 HCAPLUS
CN Urea, N-(1,3-diphenyl-1H-pyrazol-5-yl)-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-56-1 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-57-2 HCAPLUS
CN Urea, N-[1-(2-benzothiazolyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-58-3 HCAPLUS
CN Urea, N-[1-(6-chloro-3-pyridazinyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-

N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-59-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(2,6-dimethyl-4-pyrimidinyl)-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-61-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-62-9 HCAPLUS
CN Urea, N-[1-(4-fluorophenyl)-3-(tetrahydro-2-furanyl)-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-63-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-[4-(methylsulfonyl)phenyl]-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-64-1 HCAPLUS
CN Urea, N-[3-cyclopropyl-1-[4-(1,1-dimethylethyl)phenyl]-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 642085-65-2 HCAPLUS
CN Urea, N-[1-(4-fluorophenyl)-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-yl]-N'-[4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



IT **642085-13-0P**, (4-Fluoro-3-hydroxymethylphenyl)carbamic acid tert-butyl ester **642085-14-1P**, [4-Fluoro-3-(((pyrazin-2-yl)oxy)methyl)phenyl]carbamic acid tert-butyl ester
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 3-[heteroarylmethoxy]pyridines and their analogs as p38 map kinase inhibitors for treatment of arthritis)
RN 642085-13-0 HCAPLUS

CN Carbamic acid, [4-fluoro-3-(hydroxymethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 642085-14-1 HCAPLUS
CN Carbamic acid, [4-fluoro-3-[(pyrazinyloxy)methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:892762 HCAPLUS
DOCUMENT NUMBER: 139:395938
TITLE: Preparation of ureas as positive allosteric modulators of the nicotinic acetylcholine receptor
INVENTOR(S): Piotrowski, David W.; Rogers, Bruce N.; McWhorter, William W., Jr.; Walker, Daniel P.; Corbett, Jeffrey W.; Groppi, Vincent E., Jr.; Rudmann, Daniel G.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093250	A2	20031113	WO 2003-US11493	20030428

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,

GW, ML, MR, NE, SN, TD, TG
US 2003236287 A1 20031225 US 2003-423062 20030425
PRIORITY APPLN. INFO.: US 2002-377364P P 20020503
US 2003-456941P P 20030324
OTHER SOURCE(S): MARPAT 139:395938
AB ANHCXNHB [X = O, S; A = (un)substituted Ph, 6-membered N heteroaryl; B = (un)substituted 5-6-membered heteroaryl] were prepd. to treat diseases or conditions in which the α7 nAChR is known to be involved (no data). Thus, 2,4-Me(MeO)C6H3NH2 was treated with 3-F3CC6H4CNO to give 2,4-Me(MeO)C6H3NHCONHC6H4CF3-3.
IT **553661-25-9P 625120-00-5P 625120-03-8P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of ureas as pos. allosteric modulators of the nicotinic acetylcholine receptor)
RN 553661-25-9 HCAPLUS
CN Carbamic acid, [3-(trifluoromethoxy)phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 625120-00-5 HCAPLUS
CN Carbamic acid, [4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylphenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 625120-03-8 HCAPLUS
CN Carbamic acid, (5-chloro-2,4-dimethoxyphenyl)-, phenyl ester (9CI) (CA INDEX NAME)



IT **625117-68-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of ureas as pos. allosteric modulators of the nicotinic acetylcholine receptor)
RN 625117-68-2 HCAPLUS
CN Urea, N-(5-chloro-2,4-dimethoxyphenyl)-N'-1H-imidazol-2-yl- (9CI) (CA INDEX NAME)



L26 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2003:508521 HCAPLUS
DOCUMENT NUMBER: 139:86541
TITLE: N-containing heterocycle stable free radicals and rubber compositions containing them
INVENTOR(S): Tomono, Keisuke; Miyashita, Naoshi; Shimada, Atsushi
PATENT ASSIGNEE(S): Yokohama Rubber Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003183276	A2	20030703	JP 2001-380398	20011213

PRIORITY APPLN. INFO.: JP 2001-380398 20011213
OTHER SOURCE(S): MARPAT 139:86541
GI



I

AB The radicals, which are stable at room temp. in the presence of O, have N-contg. heterocycles and ≥1 hydrogen bond-formable bonds chosen from (thio)urethane, (thio)urea, (thio)amide, (thio)ester, and ether. Thus, a test piece comprising vulcanized product of a compn. comprising RSS 1 (natural rubber) 100, I (manufd. from 2,4-TDI, 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl, and 3-hydroxy-1,2,4-triazole) 0.1, HAF Shoblack N 339 (carbon black) 50, ZnO 3, sulfur 2, and other additives showed tanδ 0.1138 at 100°.

IT **552885-92-4P**
RL: IMF (Industrial manufacture); MOA (Modifier or additive use); **PREP (Preparation)**; USES (Uses)
(N-contg. heterocycle stable free radicals as heat-stabilizers for rubber compns. with good vibration damping property)

RN 552885-92-4 HCAPLUS
CN 1-Piperidinyloxy, 2,2,6,6-tetramethyl-4-[[[[2(or 4)-methyl-5-[[(1H-1,2,4-triazol-3-ylamino)carbonyl]amino]phenyl]amino]carbonyl]oxy]- (9CI) (CA INDEX NAME)



D1—Me

IT **376590-90-8P**
RL: IMF (Industrial manufacture); **RCT (Reactant)**; PREP (Preparation); RACT (Reactant or reagent)
(N-contg. heterocycle stable free radicals as heat-stabilizers for rubber compns. with good vibration damping property)

RN 376590-90-8 HCAPLUS

CN 1-Piperidinyloxy, 4-[[[[3(or 5)-isocyanato-4(or 2)-methylphenyl]amino]carbonyl]oxy]-2,2,6,6-tetramethyl- (9CI) (CA INDEX NAME)



D1—Me

L26 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER:	2002:428885 HCAPLUS
DOCUMENT NUMBER:	137:6179
TITLE:	Preparation of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors
INVENTOR(S):	Cheung, Mui; Harris, Philip Anthony; Hasegawa, Masaichi; Ida, Satoru; Kano, Kazuya; Nishigaki, Naohiko; Sato, Hideyuki; Veal, James Martin; Washio, Yoshiaki; West, Rob I.
PATENT ASSIGNEE(S):	Glaxo Group Limited, UK; Glaxosmithkline K.K.
SOURCE:	PCT Int. Appl., 217 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044156	A2	20020606	WO 2001-US44553	20011128
WO 2002044156	A3	20021017		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002032439	A5	20020611	AU 2002-32439	20011128
EP 1341771	A2	20030910	EP 2001-991963	20011128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517080	T2	20040610	JP 2002-546526	20011128
US 2004082583	A1	20040429	US 2003-433128	20031112

PRIORITY APPLN. INFO.:	US 2000-253868P	P	20001129
	US 2001-310939P	P	20010808
	WO 2001-US44553	W	20011128

OTHER SOURCE(S): MARPAT 137:6179
GI



I



II

AB The title compds. [I; E = (un)substituted aryl, heteroaryl; A = aryl, heteroaryl, heterocyclyl; X = S, O, SO2, SO, CH2, CHOH, CO; Z = O, S; p = 0-1; q = 0-1; D = CH, T = CR8, M = C and Q = NT7p, wherein p = 0 and q = 1; or D = CH, T = CR8, M = C and Q = NR7p, wherein p =1 and q = 0, or D = CH, T = CR8, M = C and Q = S or O, wherein q = 0; or D = N, T = CR8, M = C and Q = NR7p, wherein either p or q = 0 and the other = 1; or D = CH, T = N, M = C and Q = NR7p, wherein either p or q = 0 and the other = 1; or D = CH, T = CR8, M = N and Q = CH, wherein q = 0; R1 = alkyl, haloalkyl, aryl, etc.; R2 = H, alkyl, aryl, etc.; R3 = alkylene or alkylene substituted by oxo, and is linked together with N atom to which it is attached and to one of the benzimidazole N atoms to form a heterocyclic compd. fused to the benzimidazole; R7 = H, alkyl, etc.; R8 = H, halo] and their salts, useful in the treatment of hyperproliferative diseases, were prepd. Thus, reacting Me [5-(4-aminophenoxy)-1H-benzimidazol-2-yl]carbamate (prepn. given) with 3-chlorophenyl isocyanate in THF afforded 69% II which showed pIC50 of > 7.0 in TIE-2 and VEGFR2 enzyme assays.

IT **433225-52-6P 433225-66-2P 433225-79-7P**
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); **PREP (Preparation)**; USES (Uses)
(prepn. of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors)

RN 433225-52-6 HCAPLUS

CN Acetamide, N-[5-[4-[[[[5-(4-morpholinyl)-1H-1,2,4-triazol-3-yl]amino]carbonyl]amino]phenoxy]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 433225-66-2 HCAPLUS
CN Acetamide, 2-(2-methoxyethoxy)-N-[5-[4-[[[[5-(4-morpholinyl)-1H-1,2,4-triazol-3-yl]amino]carbonyl]amino]phenoxy]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CH2—CH2—OMe

RN 433225-79-7 HCAPLUS
CN 2-Furancarboxamide, N-[5-[4-[[[[5-(4-morpholinyl)-1H-1,2,4-triazol-3-yl]amino]carbonyl]amino]phenoxy]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



IT **433225-36-6P 433225-37-7P 433225-38-8P**
433225-86-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors)

RN 433225-36-6 HCAPLUS
CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[4-[[2-[[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-1H-benzimidazol-5-yl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 433225-37-7 HCAPLUS
CN Urea, N-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl]oxy]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX

NAME)



RN 433225-38-8 HCAPLUS
CN Urea, N-[4-[[2-[[[[4-(dimethylamino)phenyl]amino]carbonyl]amino]-1H-benzimidazol-5-yl]oxy]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 433225-86-6 HCAPLUS
CN Urea, N-[4-[[2-[[[(2,3-dimethylphenyl)amino]carbonyl]amino]-1H-benzimidazol-5-yl]oxy]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)



IT **54840-15-2**, 4-(tert-Butoxycarbonyl)aminophenol **433226-40-5**
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(prepn. of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors)
RN 54840-15-2 HCAPLUS
CN Carbamic acid, (4-hydroxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 433226-40-5 HCAPLUS
CN Carbamic acid, [6-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenoxy]-1H-imidazo[4,5-b]pyridin-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



IT **433226-08-5P**, 2-Nitro-5-(4-(tert-butoxycarbonylamino)phenoxy)pyridin-3-ylamine
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors)
RN 433226-08-5 HCAPLUS
CN Carbamic acid, [4-[(5-amino-6-nitro-3-pyridinyl)oxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L26 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:314913 HCAPLUS
DOCUMENT NUMBER: 136:340689
TITLE: Preparation of urea derivatives containing nitrogenous aromatic ring compounds as inhibitors of angiogenesis
INVENTOR(S): Funahashi, Yasuhiro; Tsuruoka, Akihiko; Matsukura, Masayuki; Haneda, Toru; Fukuda, Yoshio; Kamata, Junichi; Takahashi, Keiko; Matsushima, Tomohiro; Miyazaki, Kazuki; Nomoto, Kenichi; Watanabe, Tatsuo; Obaishi, Hiroshi; Yamaguchi, Atsumi; Suzuki, Sachi; Nakamura, Katsuji; Mimura, Fusayo; Yamamoto, Yuji; Matsui, Junji; Matsui, Kenji; Yoshiba, Takako; Suzuki, Yasuyuki; Arimoto, Itaru
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 699 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032872	A1	20020425	WO 2001-JP9221	20011019
WO 2002032872	C1	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001095986	A5	20020429	AU 2001-95986	20011019

EP 1415987 A1 20040506 EP 2001-976786 20011019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR
NO 2003001731 A 20030619 NO 2003-1731 20030414
US 2004053908 A1 20040318 US 2003-420466 20030418
PRIORITY APPLN. INFO.: JP 2000-320420 A 20001020
JP 2000-386195 A 20001220
JP 2001-46685 A 20010222
WO 2001-JP9221 W 20011019
OTHER SOURCE(S): MARPAT 136:340689
GI

Q= 

AB N-aryl or N-heteroarylurea derivs. represented by the general formula Ag-Xg-Yg-Tg1 or salts thereof, or hydrates of both [wherein Ag = (un)substituted C6-14 aryl or 5- to 14-membered heterocyclic group; Xg = single bond, O, S, C1-6 alkylene, SO, SO2, (un)substituted NH; Yg = (un)substituted C6-14 aryl, 5- to 14-membered heterocyclic group, C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl-C1-6 alkyl, 5- to 14-membered heteroaryl-C1-6 alkyl, (CH2)gSO2 (g = 1-8), (CH2)faCH:CH(CH2)fb (fa, fb = 0, 1,2,3), etc.; and Tg1 = a group of the general formula -Eg-CO-NRg1(Zg) or Q; wherein Eg = a single bond, (un)substituted NH; Rg1 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 aliph. hydrocarbyl, etc.; Zg = C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl, etc.; Zg1, Zg2 = (a) a single bond, (b) C1-6 alkylene optionally having ≥1 atoms selected from O, S, and N in the middle or the terminus of the chain and optionally substituted with oxo, (c) (un)substituted C2-6 alkenyl] are prepd. These compds. are also inhibitors of vascular endothelial growth factor receptor kinase (VEGFR2 kinase) and are useful as antitumor agents against hemangioma, pancreatic cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, lung cancer, brain tumor, leukemia, or ovarian cancer, as cancer metastasis inhibitors, and for the treatment of retina neovascularization, diabetic retinopathy, atherosclerosis, or inflammatory diseases such as osteoarthritis, rheumatoid arthritis, psoriasis, or delayed hypersensitivity. Thus, to soln. of 334 mg 4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenylamine in 4 mL DMF were added 0.066 mL pyridine and 0.102 mL Ph chlorocarbonate and stirred at room temp. for 2.5 h to give 330 mg N-[4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea which (260 mg) was hydrogenolyzed over platinum oxide in ethanol overnight to give 160 mg N-[4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea (I). I showed IC50 of 0.02 nM for inhibiting the vascular endothelial growth factor (VEGF)-stimulated sandwich tube formation in vascular endothelial cell.

IT **417713-01-0P 417713-68-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)

(prepn. of urea derivs. contg. nitrogenous arom. ring compds. as angiogenesis inhibitors for prevention or treatment of diseases)

RN 417713-01-0 HCAPLUS

CN Urea, N-[4-[[6-cyano-7-(2-methoxyethoxy)-4-quinolinyl]oxy]phenyl]-N'-1H-imidazol-2-yl- (9CI) (CA INDEX NAME)



RN 417713-68-9 HCAPLUS

CN Urea, N-1H-benzimidazol-2-yl-N'-[4-[[6-cyano-7-(2-methoxyethoxy)-4-quinolinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



IT **4930-03-4**, Phenylcarbamic acid phenyl ester

RL: **RCT (Reactant)**; RACT (Reactant or reagent)

(prepn. of urea derivs. contg. nitrogenous arom. ring compds. as angiogenesis inhibitors for prevention or treatment of diseases)

RN 4930-03-4 HCAPLUS

CN Carbamic acid, phenyl-, phenyl ester (9CI) (CA INDEX NAME)



IT **65141-00-6P** **65141-04-0P** **347151-53-5P**
417721-09-6P **417721-10-9P** **417721-11-0P**
417721-13-2P **417721-32-5P** **417721-91-6P**
417722-40-8P **417722-53-3P** **417722-83-9P**
417722-87-3P **417722-91-9P** **417722-95-3P**
417722-99-7P **417723-05-8P** **417723-09-2P**
417723-58-1P **417723-70-7P** **417723-73-0P**
417723-76-3P **417723-78-5P** **417723-81-0P**
417724-07-3P **417724-17-5P** **417724-33-5P**

417724-40-4P **417724-41-5P** **417724-46-0P**
417724-54-0P **417724-59-5P** **417724-65-3P**
417724-88-0P, 4-[2-[(4-[3-Chloro-4-[(phenoxycarbonyl)amino]phenoxy
]-2-pyridyl)amino]-2-oxoethyl]-1-piperidinecarboxylic acid tert-butyl
ester
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(prepn. of urea derivs. contg. nitrogenous arom. ring compds. as
angiogenesis inhibitors for prevention or treatment of diseases)

RN 65141-00-6 HCAPLUS
CN Carbamic acid, (2,4-difluorophenyl)-, phenyl ester (9CI) (CA INDEX NAME)



RN 65141-04-0 HCAPLUS
CN Carbamic acid, (4-fluorophenyl)-, phenyl ester (9CI) (CA INDEX NAME)



RN 347151-53-5 HCAPLUS
CN Carbamic acid, [4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-, phenyl ester
(9CI) (CA INDEX NAME)



RN 417721-09-6 HCAPLUS
CN Carbamic acid, [4-[[6-cyano-7-(2-methoxyethoxy)-4-quinolinyl]oxy]phenyl]-,
phenyl ester (9CI) (CA INDEX NAME)



RN 417721-10-9 HCAPLUS
CN Carbamic acid, [4-[[6-cyano-7-(2-methoxyethoxy)-4-quinolinyl]oxy]-2-fluorophenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417721-11-0 HCAPLUS
CN Carbamic acid, [4-[(6-cyano-7-methoxy-4-quinolinyl)oxy]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417721-13-2 HCAPLUS
CN Carbamic acid, [3-(methylsulfonyl)phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417721-32-5 HCAPLUS

CN Carbamic acid, [4-[[6-cyano-7-(phenylmethoxy)-4-quinolinyl]oxy]-2-fluorophenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417721-91-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[3-chloro-4-[(phenoxycarbonyl)amino]phenoxy]-2-pyridinyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 417722-40-8 HCAPLUS

CN 6-Quinolinecarboxylic acid, 4-[3-chloro-4-[(phenoxycarbonyl)amino]phenoxy]-7-(2-methoxyethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 417722-53-3 HCAPLUS

CN Carbamic acid, [4-[[6-(aminocarbonyl)-7-methoxy-4-quinolinyl]oxy]-3-methylphenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417722-83-9 HCAPLUS
CN Carbamic acid, [4-[[6-(aminocarbonyl)-7-methoxy-4-quinolinyl]oxy]-2-fluorophenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417722-87-3 HCAPLUS
CN Carbamic acid, [4-[[6-(aminocarbonyl)-7-(2-methoxyethoxy)-4-quinolinyl]oxy]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417722-91-9 HCAPLUS
CN Carbamic acid, [4-[[6-(aminocarbonyl)-7-(2-methoxyethoxy)-4-quinolinyl]oxy]-2-fluorophenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417722-95-3 HCAPLUS
CN Carbamic acid, [4-[[6-(aminocarbonyl)-7-methoxy-4-quinolinyl]oxy]-2-chlorophenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417722-99-7 HCAPLUS
CN Carbamic acid, [4-[[6-(aminocarbonyl)-7-(phenylmethoxy)-4-quinolinyl]oxy]-2-fluorophenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417723-05-8 HCAPLUS
CN Carbamic acid, [4-[[6-(aminocarbonyl)-7-(phenylmethoxy)-4-quinolinyl]oxy]-2-chlorophenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417723-09-2 HCAPLUS
CN 6-Quinolinecarboxylic acid, 4-[3-chloro-4-[(phenoxycarbonyl)amino]phenoxy]-7-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 417723-58-1 HCAPLUS
CN Carbamic acid, [4-[[2-[(1-oxobutyl)amino]-4-pyridinyl]oxy]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417723-70-7 HCAPLUS
CN Carbamic acid, [4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417723-73-0 HCAPLUS
CN Carbamic acid, [4-[[6-(aminocarbonyl)-7-methoxy-4-quinolinyl]oxy]-2-methylphenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417723-76-3 HCAPLUS
CN Carbamic acid, [4-[[6-(aminocarbonyl)-7-methoxy-4-quinolinyl]oxy]-2-(trifluoromethyl)phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417723-78-5 HCAPLUS
CN Carbamic acid, [4-[[6-(aminocarbonyl)-7-methoxy-4-quinolinyl]oxy]-2,3-dimethylphenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417723-81-0 HCAPLUS
CN Carbamic acid, [4-[[6-(aminocarbonyl)-7-methoxy-4-quinolinyl]oxy]-2,5-dimethylphenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417724-07-3 HCAPLUS
CN Carbamic acid, [4-[[6-cyano-7-[(2R)-oxiranylmethoxy]-4-quinolinyl]oxy]-2-fluorophenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 417724-17-5 HCAPLUS
CN Carbamic acid, [2-chloro-5-[[6-cyano-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]-4-quinolinyl]oxy]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 417724-33-5 HCAPLUS
CN Carbamic acid, [4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-fluorophenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417724-40-4 HCAPLUS
CN Carbamic acid, [4-[[6-cyano-7-[3-(1-piperidinyl)propoxy]-4-quinolinyl]oxy]-2-fluorophenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417724-41-5 HCAPLUS
CN Carbamic acid, [2-chloro-4-[[6-cyano-7-(phenylmethoxy)-4-quinolinyl]oxy]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417724-46-0 HCAPLUS
CN Carbamic acid, [2-chloro-4-[[6-[(methylamino)carbonyl]-7-(phenylmethoxy)-4-quinolinyl]oxy]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417724-54-0 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[6-cyano-4-[3-fluoro-4-[(phenoxycarbonyl)amino]phenoxy]-7-quinolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 417724-59-5 HCAPLUS
CN 6-Quinolinecarboxylic acid, 4-[3-fluoro-4-[(phenoxycarbonyl)amino]phenoxy]-7-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 417724-65-3 HCAPLUS
CN Carbamic acid, [4-[[6-cyano-7-(phenylmethoxy)-4-quinolinyl]oxy]-2,3-dimethylphenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 417724-88-0 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-[[4-[3-chloro-4-[(phenoxycarbonyl)amino]phenoxy]-2-pyridinyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:468189 HCAPLUS
DOCUMENT NUMBER: 135:61321
TITLE: Methods for the solid phase synthesis of combinatorial libraries of benzimidazoles, benzoxazoles, benzothiazoles and derivatives for use as peptidomimetics
INVENTOR(S): Laborde, Edgardo; Matsumoto, Yukiharu
PATENT ASSIGNEE(S): Telik, Inc., USA
SOURCE: U.S., 18 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6251689	B1	20010626	US 1999-313568	19990514
US 2001024833	A1	20010927	US 2001-775644	20010205

PRIORITY APPLN. INFO.: US 1998-85465P P 19980514
US 1999-313568 A1 19990514

OTHER SOURCE(S): CASREACT 135:61321

AB The present invention provides an efficient and versatile method for the synthesis and screening of combinatorial libraries of benzimidazoles, benzoxazoles, benzothiazoles, and derivs. thereof. Thus, resin-bound 4-carboxybenzaldehyde in DMA is treated with 1,2-phenylenediamine and TCNE to give 2-(4-carboxyphenyl)benzimidazole. In order to expedite the synthesis of large arrays of compds. possessing these core structures, a general methodol. for solid phase synthesis of these derivs. is provided. Arrays of benzimidazoles, benzoxazoles, benzothiazoles, and derivs. thereof useful as peptidomimetics and for the identification of agents having antifungal, antiviral, antimicrobial, anticoagulant, and antiulcer activity, or use in the treatment of inflammation, hypertension, cancer, and other conditions can be prepd. by this method.

IT **345958-22-7D**, resin bound
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(methods for the solid phase synthesis of combinatorial libraries of benzimidazoles, benzoxazoles, benzothiazoles and derivs. for use as peptidomimetics)

RN 345958-22-7 HCAPLUS
CN Benzoic acid, 3,4-bis[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)



IT **345958-14-7P 345958-15-8P 345958-17-0P**
RL: SPN (Synthetic preparation); **PREP (Preparation)**
(methods for the solid phase synthesis of combinatorial libraries of benzimidazoles, benzoxazoles, benzothiazoles and derivs. for use as peptidomimetics)

RN 345958-14-7 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 345958-15-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 345958-17-0 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[(phenylamino)carbonyl]amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:666713 HCAPLUS
DOCUMENT NUMBER: 133:252426
TITLE: Preparation of aromatic heterocyclic ureas as antiinflammatory agents
INVENTOR(S): Betageri, Rajashehar; Breitfelder, Steffen; Cirillo, Pier F.; Gilmore, Thomas A.; Hickey, Eugene R.; Kirrane, Thomas M.; Moriak, Monica H.; Moss, Neil; Patel, Usha R.; Proudfoot, John R.; Regan, John R.; Sharma, Rajiv; Sun, Sanxing; Swinamer, Alan D.; Takahashi, Hidenori
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 282 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000055139	A2	20000921	WO 2000-US3865	20000216
WO 2000055139	A3	20010426		
W: AE, AU, BG, BR, BY, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, VN, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1165516	A2	20020102	EP 2000-907295	20000216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

BR	2000008922	A	20020115	BR 2000-8922	20000216
TR	200102817	T2	20020521	TR 2001-200102817	20000216
JP	2002539198	T2	20021119	JP 2000-605569	20000216
EE	200100483	A	20021216	EE 2001-483	20000216
NZ	514711	A	20040227	NZ 2000-514711	20000216
AU	771273	B2	20040318	AU 2000-28817	20000216
BG	105880	A	20020531	BG 2001-105880	20010905
ZA	2001007446	A	20020910	ZA 2001-7446	20010910
HR	2001000665	A1	20030630	HR 2001-665	20010910
NO	2001004412	A	20010911	NO 2001-4412	20010911
US	2002055507	A1	20020509	US 2001-962709	20010925
US	6660732	B2	20031209		
US	2002082256	A1	20020627	US 2001-962057	20010925
US	6656933	B2	20031202		
US	2003225077	A1	20031204	US 2003-424613	20030428
US	2004019038	A1	20040129	US 2003-624289	20030721

PRIORITY APPLN. INFO.:

US	1999-124148P	P	19990312
US	1999-165867P	P	19991116
US	2000-505582	A3	20000216
WO	2000-US3865	W	20000216
US	2001-962057	A1	20010925
US	2001-962709	A3	20010925

OTHER SOURCE(S): MARPAT 133:252426

GI



I



II

AB The title compds. (I) [wherein Ar1 = (un)substituted pyrrole, pyrrolidine, pyrazole, imidazole, oxazole, thiazole, furan, or thiophene; Ar2 = (un)substituted Ph, (tetrahydro)naphthyl, (tetrahydro)quinoline, (tetrahydro)isoquinoline, benzimidazole, benzofuran, indanyl, indenyl, or indole; W = O or S; X = (un)substituted cycloalkyl, cycloalkenyl, Ph, furan, thiophene, pyrrole, imidazolyl, pyridine, pyrimidine, (dihydro)pyridinone, (dihydro)maleimide, piperidine, piperazine, or pyrazine; Y = a bond or (un)substituted satd. or unsatd. alkyl optionally interrupted by O, NH, S(O), SO2, or S; Z = (un)substituted Ph, pyridine, pyrimidine, pyridazine, imidazole, (tetrahydro)furan, thiophene, (tetrahydro)pyran, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxane, (thio)morpholine (sulfoxide), piperidine, cyclohexanone, pentamethylene sulfoxide, etc.] were prepd. for the treatment of diseases or pathol.

conditions involving inflammation, such as chronic inflammatory diseases. Thus, coupling 2-cyclohexenone with 4-bromo-1-naphthylamine in the presence of Pd(PPh3)2Cl2, DPPP, and NaHCO3 in DMF, followed by conversion of the amine to an isocyanate using ClCOCl and immediate addn. of 1-(4-methylphenyl)-3-tert-butyl-1H-pyrazol-5-amine, gave the urea II. In a cytokine prodn. inhibition assay, preferred compds. of the invention showed IC50 < 10 .mu.M against TNF-.alpha. in lipopolysaccharide stimulated THF cells.

IT **294851-78-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)

(prepn. of arom. heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addn. of heterocyclic amines)

RN 294851-78-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-□(3-oxo-1-cyclohexen-1-yl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



IT **294848-43-4P 294848-46-7P 294848-49-0P**
294848-51-4P 294848-53-6P 294848-55-8P
294848-58-1P 294848-61-6P 294848-64-9P
294848-67-2P 294848-70-7P 294848-73-0P
294848-76-3P 294848-79-6P 294848-82-1P
294848-85-4P 294848-88-7P 294848-91-2P
294848-94-5P 294848-96-7P 294848-98-9P
294849-00-6P 294849-02-8P 294849-04-0P
294849-06-2P 294849-08-4P 294849-10-8P
294849-12-0P 294849-14-2P 294849-16-4P
294849-18-6P 294849-20-0P 294849-22-2P
294849-24-4P 294849-26-6P 294849-28-8P
294849-30-2P 294849-32-4P 294849-34-6P
294849-36-8P 294849-38-0P 294849-40-4P
294849-42-6P 294849-44-8P 294849-46-0P
294849-48-2P 294849-50-6P 294849-52-8P
294849-54-0P 294849-56-2P 294849-58-4P
294849-60-8P 294849-62-0P 294849-64-2P
294849-66-4P 294849-68-6P 294851-79-9P
294851-81-3P 294851-83-5P 294851-85-7P
294853-11-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of arom. heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addn. of heterocyclic amines)

RN 294848-43-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[4-(4-morpholinylmethyl)phenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-46-7 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[2-(4-morpholinyl)ethyl]phenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-49-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[3-(4-morpholinylmethyl)phenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 294848-51-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-53-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[5-(4-morpholinylmethyl)-2-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-55-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-□
[5-(4-morpholinylmethyl)-2-furanyl]-1-naphthalenyl]- (9CI) (CA INDEX
NAME)

PAGE 1-A



PAGE 2-A



RN 294848-58-1 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-□
N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA
INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-61-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[6-(4-□
morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-64-9 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[3-[[2-(2-pyridinyl)ethyl]amino]-1-cyclohexen-1-yl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 294848-67-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[4-[[(3-pyridinylmethyl)amino]methyl]phenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-70-7 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[4-(4-morpholinylmethyl)phenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-73-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[6-[(4-hydroxybutyl)amino]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



NH—(CH 2)4—OH

RN 294848-76-3 HCAPLUS

CN Benzamide, 5-[3-(1,1-dimethylethyl)-5-[[[[4-[6-(4-morpholinylmethyl)-3-□ pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]-1H-pyrazol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-79-6 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-□ N'-[4-[4-[(3-hydroxy-1-piperidinyl)methyl]phenyl]-1-naphthalenyl]- (9CI)

(CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-82-1 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[4-[(4-oxido-4-morpholinyl)methyl]phenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-85-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[3-(4-morpholinylmethyl)-1-cyclohexen-1-yl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 294848-88-7 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[3-hydroxy-4-[(tetrahydro-3-furanyl)methyl]phenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-91-2 HCAPLUS
CN Urea, N-[4-[4-[[bis(2-methoxyethyl)amino]methyl]phenyl]-1-naphthalenyl]-N'-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-94-5 HCAPLUS

CN Urea, N-[4-[6-(3-cyanopropoxy)-3-pyridinyl]-1-naphthalenyl]-N'-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 294848-96-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[4-(4-morpholinylmethyl)-1-piperidinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294848-98-9 HCAPLUS
CN Urea, N-[4-[4-[[bis(2-cyanoethyl)amino]methyl]phenyl]-1-naphthalenyl]-N'-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-00-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[4-(2-furanylmethyl)-3-hydroxyphenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-02-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-□
N'-[4-[4-(4-thiomorpholinylmethyl)phenyl]-1-naphthalenyl]- (9CI) (CA
INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-04-0 HCAPLUS
CN 3-Piperidinecarboxamide, 1-[[4-[4-[[[[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]-1-naphthalenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-06-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[4-[(2-methyl-3-oxo-1-piperazinyl)methyl]phenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-08-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(2-methyl-5-pyrimidinyl)-1H-pyrazol-5-yl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-10-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-□
N'-[4-[6-(4-hydroxybutoxy)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 294849-12-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)[1,4'-bi-1H-pyrazol]-5-yl]-N'-[4-[6-(4-□
morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-14-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-□
N'-[4-[6-[(tetrahydro-2H-thiopyran-4-yl)amino]-3-pyridinyl]-1-□
naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-16-4 HCAPLUS
CN Urea, N-[1-(2-cyanoethyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[4-[6-□
(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-18-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-□
N'-[4-[6-[(2,6-dimethyl-4-morpholinyl)methyl]-3-pyridinyl]-1-naphthalenyl]-□
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-20-0 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-22-2 HCAPLUS
CN Urea, N-[1-(6-amino-3-pyridinyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-24-4 HCAPLUS
CN Morpholine, 4-[[5-[4-[[[[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]-1-naphthalenyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-26-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-□
N'-[4-[6-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-3-pyridinyl]-1-□
naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-28-8 HCAPLUS
CN Urea, N-[4-[4-[[(2-cyanoethyl)(3-pyridinylmethyl)amino]methyl]phenyl]-1-□
naphthalenyl]-N'-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-□
pyrazol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-30-2 HCAPLUS
CN Urea, N-[4-[4-[[(2-cyanoethyl)[(tetrahydro-2-furanyl)methyl]amino]methyl]p□
henyl]-1-naphthalenyl]-N'-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-□
1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-32-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[4-methoxy-6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-34-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[6-[1-(4-morpholinyl)propyl]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-36-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1'-methyl[1,4'-bi-1H-pyrazol]-5-yl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-38-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-□
N'-[4-[6-[(tetrahydro-1-oxido-2H-thiopyran-4-yl)amino]-3-pyridinyl]-1-□
naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-40-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[6-[(tetrahydro-2H-pyran-4-yl)amino]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 294849-42-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-pyrazol-5-yl]-N'-[4-[5-[(tetrahydro-2H-thiopyran-4-yl)amino]pyrazinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-44-8 HCAPLUS
CN Acetamide, N-[5-[4-[[[[3-(1,1-dimethylethyl)-1-(6-methyl-3-pyridinyl)-1H-□
pyrazol-5-yl]amino]carbonyl]amino]-1-naphthalenyl]-2-pyridinyl]- (9CI)
(CA INDEX NAME)□



RN 294849-46-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1'-[3-(methylthio)propyl][1,4'-bi-1H-□
pyrazol]-5-yl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]-□

(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-48-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(2-methyl-5-pyrimidinyl)-1H-pyrazol-5-yl]-□
N'-[4-[6-[(1-oxido-4-thiomorpholinyl)methyl]-3-pyridinyl]-1-naphthalenyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-50-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(2-methyl-5-pyrimidinyl)-1H-pyrazol-5-yl]-N'-[4-[6-[(tetrahydro-2H-pyran-4-yl)amino]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-52-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-[2-(methylthio)-5-pyrimidinyl]-1H-pyrazol-5-yl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-54-0 HCAPLUS
CN Urea, N-[1-(2-amino-5-pyrimidinyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-56-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1'-methyl[1,4'-bi-1H-pyrazol]-5-yl]-N'-[4-□
[4-(4-morpholinylmethyl)phenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-58-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-□
[6-[(tetrahydro-1-oxido-2H-thiopyran-4-yl)amino]-3-pyridinyl]-1-□
naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-60-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[6-(4-thiomorpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-62-0 HCAPLUS
CN Morpholine, 4-[[5-[4-[[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]-1-naphthalenyl]-2-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-64-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[2-(4-morpholinylmethyl)-5-pyrimidinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-66-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-□
[6-[(1-oxido-4-thiomorpholinyl)methyl]-3-pyridinyl]-1-naphthalenyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-68-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(2-methyl-5-pyrimidinyl)-1H-pyrazol-5-yl]-N'-[4-[2-(4-morpholinylmethyl)-5-pyrimidinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-79-9 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[3-(4-morpholinyl)-1-cyclohexen-1-yl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 294851-81-3 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[4-(4-morpholinyl)phenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-83-5 HCAPLUS
CN Urea, N-[4-[4-[(dimethylamino)methyl]phenyl]-1-naphthalenyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



Me 2N—CH 2

RN 294851-85-7 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[3-(4-morpholinyl)-1-cyclohepten-1-yl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 294853-11-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[3-(4-morpholinyl)phenyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



IT **261711-84-6P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arom. heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addn. of heterocyclic amines)

RN 261711-84-6 HCAPLUS
CN Carbamic acid, [5-(1,1-dimethylethyl)-2-methylphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L26 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:493269 HCAPLUS
DOCUMENT NUMBER: 133:105343
TITLE: Preparation of β-phenylalanine derivatives as integrin antagonists
INVENTOR(S): Schoop, Andreas; Muller, Gerhard; Bruggemeier, Ulf; Schmidt, Delf; Stelte-Ludwig, Beatrix; Keldenich, Jorg; Albers, Markus
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041469	A2	20000720	WO 2000-EP120	20000111
WO 2000041469	A3	20001116		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,

CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6291503	B1	20010918	US 1999-232738	19990115
CA 2360356	AA	20000720	CA 2000-2360356	20000111
EP 1147079	A2	20011024	EP 2000-903571	20000111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002534439	T2	20021015	JP 2000-593094	20000111
US 2001031788	A1	20011018	US 2001-867835	20010530
US 6589972	B2	20030708		

PRIORITY APPLN. INFO.: US 1999-232738 A 19990115
WO 2000-EP120 W 20000111

OTHER SOURCE(S): MARPAT 133:105343

GI



I

AB β-Phenylalanine derivs. I [R1 = H, (un)substituted alkyl, cycloalkyl, aryl, heterocyclyl; R2, R3 = any group given for R1 or (un)substituted alkenyl or alkynyl, OH, alkoxy or R2 and R3 are bonded to each other; R4 = carboxy ester, SO2H, CHO, CONH2, C(S)NH2 or their derivs.; R5 = H, (un)substituted alkyl, cycloalkyl, aryl; R6 = any group given for R1 or is bonded to one of R7, R8 or R9; R7 is absent, H, (un)substituted alkyl or cycloalkyl, NO2, CN, CHO or CO2H or their derivs., or is bonded to one of R6, R8, or R9; R8, R9 = any group given for R1 or is bonded to one of R6, R7 or R9 or R8; R10, R11 = H, (un)substituted alkyl, cycloalkyl, or alkoxy, halo; L is a sulfonamide, amide, ether, ester, keto, urea, thioether, sulfoxide or sulfone unit optionally extended by one or two methylene groups; X is N, O or S] and their physiol. acceptable salts and stereoisomers were prepd. Thus, 3-[(phenylsulfonyl)amino]-3-[3-[(3-guanidinophenyl)sulfonyl]phenyl]propionic acid trifluoroacetic acid salt, prepd. by a multistep procedure from 3-nitrobenzaldehyde, ammonium acetate, malonic acid, benzenesulfonyl chloride, 3-nitrobenzenesulfonyl chloride, and 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, showed IC50 = 19 nM antagonist activity against integrin αvβ3 receptor.

IT **283613-04-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of β-phenylalanine derivs. as integrin antagonists)

RN 283613-04-7 HCAPLUS
CN Benzenepropanoic acid, 3-[[[3-[[(1H-benzimidazol-2-ylamino)carbonyl]amino]phenyl]sulfonyl]amino]-β-[[(phenylmethoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)



IT **283613-53-6P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of β-phenylalanine derivs. as integrin antagonists)

RN 283613-53-6 HCAPLUS
CN Benzenepropanoic acid, 3-[[[3-[(ethoxythioxomethyl)amino]phenyl]sulfonyl]amino]-β-[(phenylsulfonyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



L26 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:401817 HCAPLUS
DOCUMENT NUMBER: 133:30667
TITLE: Heteroaryl-containing thiourea derivatives useful as inhibitors of herpes viruses
INVENTOR(S): Bloom, Jonathan David; Digrandi, Martin Joseph; Dushin, Russell George; Lang, Stanley Albert; O'Hara, Bryan Mark
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034269	A1	20000615	WO 1999-US28892	19991206
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6166028	A	20001226	US 1999-444782	19991122
US 6197803	B1	20010306	US 1999-447006	19991122

US 6201013	B1	20010313	US 1999-444075	19991122
EP 1140913	A1	20011010	EP 1999-965143	19991206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101598	T2	20011022	TR 2001-200101598	19991206
BR 9916042	A	20011204	BR 1999-16042	19991206
JP 2002531558	T2	20020924	JP 2000-586716	19991206
AU 756043	B2	20030102	AU 2000-31122	19991206
US 6262082	B1	20010717	US 2000-669483	20000925
US 6271236	B1	20010807	US 2000-669943	20000926
ZA 2001004373	A	20020918	ZA 2001-4373	20010528
NO 2001002836	A	20010808	NO 2001-2836	20010608
BG 105580	A	20020131	BG 2001-105580	20010608
US 2003036653	A1	20030220	US 2002-99695	20020315
US 6555561	B2	20030429		

PRIORITY APPLN. INFO.:

US 1998-208540	A	19981209
US 1998-150692P	P	19981209
US 1998-150698P	P	19981209
US 1998-155192P	P	19981209
US 1998-155240P	P	19981209
US 1998-208164	A	19981209
US 1998-208561	A	19981209
US 1999-444782	A3	19991122
WO 1999-US28892	W	19991206
US 2000-669535	A3	20000926

OTHER SOURCE(S): MARPAT 133:30667

GI



I



II

AB Title compds. I and related compds. are disclosed [wherein R1-R5 = H, C1-6 alkyl or perhaloalkyl, C2-6 alkenyl or alkynyl, C3-10 (hetero)cycloalkyl, (hetero)aryl, halo, CN, NO2, CO2R6, COR6, OR6, SR6, SOR6, SO2R6, CONR7R8, NR6N(R7R8), N(R7R8), or W-Y-(CH2)n-Z, provided that at least 1 of R1-R5 ≠ H; or R2R3 or R3R4 form 3- to 7-membered heterocycloalkyl or heteroaryl fusion; R6, R7 = H, C1-6 alkyl or perhaloalkyl, or aryl; R8 = H, C1-6 alkyl or perhaloalkyl, C3-10 (hetero)cycloalkyl, (hetero)aryl; or NR7R8 forms 3- to 7-membered heterocycloalkyl; A = heteroaryl; W = O, NR6, or bond; Y = CO, CO2, or bond; Z = C1-4 alkyl, CN, CO2R6, COR6, CONR7R8, OCOR6, NR6COR7, OCONR6, OR6, SR6, SOR6, SO2R6, SR6N(R7R8), N(R7R8) or Ph; G = aryl or heteroaryl; X = bond, NH, C1-6 alkyl, alkenyl, alkoxy, alkylthio, or alkylamino, or (CH)J; J = C1-6 alkyl, C3-7 cycloalkyl, Ph, or PhCH2; n = 1-6]. I, or pharmaceutical salts thereof, are useful in the treatment of diseases assocd. with herpes viruses, including human cytomegalovirus (HCMV), herpes simplex viruses (HSV), varicella-zoster virus (VZV), or (no data) Epstein-Barr virus, human herpesviruses-6 and

-7, and Kaposi herpesvirus. Approx. 1000 example compds. prepd. by std. methods are listed, with biol. data for approx. 25 compds. in 2-4 bioassays. For instance, the pyridinylthiazolecarboxamide deriv. II had an IC50 of 0.001 μg/mL against HCMV wild-type in human foreskin fibroblast cell culture.

IT **273384-69-3P 273384-74-0P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of heteroaryl-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 273384-69-3 HCAPLUS
CN Carbamic acid, [4-[(2-fluorobenzoyl)amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 273384-74-0 HCAPLUS
CN Carbamic acid, [4-[[2-(methylsulfinyl)benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **71026-66-9**
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(starting material; prepn. of heteroaryl-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 71026-66-9 HCAPLUS
CN Carbamic acid, (4-aminophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **273390-64-0P 273390-92-4P 273390-93-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(target compd.; prepn. of heteroaryl-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 273390-64-0 HCAPLUS
CN Benzamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 273390-92-4 HCAPLUS
CN 1,2,3-Thiadiazole-4-carboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 273390-93-5 HCAPLUS
CN 2-Furancarboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:401816 HCAPLUS
DOCUMENT NUMBER: 133:30666
TITLE: Aryl- and heteroaryl-substituted thiourea derivatives useful as inhibitors of herpes viruses
INVENTOR(S): Bloom, Jonathan David; Digrandi, Martin Joseph; Dushin, Russell George; Lang, Stanley Albert; O'Hara, Bryan Mark
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034268	A1	20000615	WO 1999-US28838	19991206

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,

	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
BR 9915993	A	20010904	BR 1999-15993		19991206	
EP 1137647	A1	20011004	EP 1999-965131		19991206	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,						
IE, SI, LT, LV, FI, RO						
JP 2002531557	T2	20020924	JP 2000-586715		19991206	
ZA 2001004318	A	20020826	ZA 2001-4318		20010525	
NO 2001002837	A	20010719	NO 2001-2837		20010608	
PRIORITY APPLN. INFO.:			US 1998-207961	A	19981209	
			WO 1999-US28838	W	19991206	

OTHER SOURCE(S): MARPAT 133:30666
GI



I



II

AB Title compds. I and related compds. and their pharmaceutical salts are disclosed [wherein A = heteroaryl; R1-R4 = H, C1-4 alkyl or perhaloalkyl, halo, C1-4 alkoxy, cyano; R1R2 or R3R4 = C5-7 aryl fusion; G = aryl or heteroaryl; and X = bond, NH, C1-6 alkyl, alkenyl, alkoxy, alkylthio, or alkylamino, or (CH)J; J = C1-6 alkyl, C3-7 cycloalkyl, Ph or PhCH2; n = 1-6]. The compds. are useful in the treatment of diseases assocd. with herpes viruses, including human cytomegalovirus (HCMV), herpes simplex viruses (HSV), and varicella-zoster virus (VZV), as well as (no data) Epstein-Barr virus, human herpesviruses-6 and -7, and Kaposi herpesvirus. Approx. 1000 example compds. prepd. by std. methods are listed, with biol. data for approx. 35 compds. in 2-4 bioassays. For instance, the pyridine deriv. II had an IC50 of 0.018 μg/mL against HCMV wild-type in human foreskin fibroblast cell culture.

IT **273384-69-3P 273384-74-0P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of heteroaryl thiourea derivs. as inhibitors of herpes viruses)

RN 273384-69-3 HCAPLUS
CN Carbamic acid, [4-[(2-fluorobenzoyl)amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 273384-74-0 HCAPLUS
CN Carbamic acid, [4-[[2-(methylsulfinyl)benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 71026-66-9
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(starting material; prepn. of heteroaryl thiourea derivs. as inhibitors of herpes viruses)
RN 71026-66-9 HCAPLUS
CN Carbamic acid, (4-aminophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **273390-64-0P 273390-92-4P 273390-93-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(target compd.; prepn. of heteroaryl thiourea derivs. as inhibitors of herpes viruses)
RN 273390-64-0 HCAPLUS
CN Benzamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 273390-92-4 HCAPLUS
CN 1,2,3-Thiadiazole-4-carboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 273390-93-5 HCAPLUS
CN 2-Furancarboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:401809 HCAPLUS
DOCUMENT NUMBER: 133:30657
TITLE: Heterocyclic carboxamide-containing thiourea derivatives containing a substituted phenylenediamine group, useful as inhibitors of herpes viruses
INVENTOR(S): Bloom, Jonathan David; Curran, Kevin Joseph; Digrandi, Martin Joseph; Dushin, Russell George; Jones, Thomas Richard; Lang, Stanley Albert; Ross, Adma Antonia; Terefenko, Eugene Anthony; O'Hara, Bryan Mark
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034261	A2	20000615	WO 1999-US28916	19991206
WO 2000034261	A3	20020131		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6166028	A	20001226	US 1999-444782	19991122
US 6197803	B1	20010306	US 1999-447006	19991122
US 6201013	B1	20010313	US 1999-444075	19991122
EP 1144399	A2	20011017	EP 1999-967213	19991206
EP 1144399	A3	20020911		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

	IE, SI, LT, LV, FI, RO			
	BR 9916043	A	20011204	BR 1999-16043 19991206
	JP 2002533301	T2	20021008	JP 2000-586708 19991206
	US 6262082	B1	20010717	US 2000-669483 20000925
	US 6271236	B1	20010807	US 2000-669943 20000926
	ZA 2001004322	A	20021025	ZA 2001-4322 20010525
	NO 2001002835	A	20010719	NO 2001-2835 20010608
	US 2003036653	A1	20030220	US 2002-99695 20020315
	US 6555561	B2	20030429	
PRIORITY APPLN. INFO.:				US 1998-208164 A 19981209
				US 1998-150692P P 19981209
				US 1998-150698P P 19981209
				US 1998-155192P P 19981209
				US 1998-155240P P 19981209
				US 1998-208540 A 19981209
				US 1998-208561 A 19981209
				US 1999-444782 A3 19991122
				WO 1999-US28916 W 19991206
				US 2000-669535 A3 20000926

OTHER SOURCE(S): MARPAT 133:30657

GI



I



II

AB Title compds. I and related compds. are disclosed [wherein R1-R5 = H, C1-6 alkyl or perhaloalkyl, C2-6 alkenyl or alkynyl, C3-10 (hetero)cycloalkyl, (hetero)aryl, halo, CN, NO2, CO2R6, COR6, OR6, SR6, SOR6, SO2R6, CONR7R8, NR6N(R7R8), N(R7R8), or W-Y-(CH2)n-Z, provided that at least 1 of R1-R5 ≠ H; or R2R3 or R3R4 form 3- to 7-membered heterocycloalkyl or heteroaryl fusion; R6, R7 = H, C1-6 alkyl or perhaloalkyl, or aryl; R8 = H, C1-6 alkyl or perhaloalkyl, C3-10 (hetero)cycloalkyl, (hetero)aryl; or NR7R8 forms 3- to 7-membered heterocycloalkyl; R9-R12 = H, C1-4 alkyl or perhaloalkyl, halo, C1-4 alkoxy, or cyano, or R9R10 or R11R12 = C5-7 aryl fusion, provided that at least 1 of R9-R12 ≠ H; W = O, NR6, or bond; Y = CO, CO2, or bond; Z = C1-4 alkyl, CN, CO2R6, COR6, CONR7R8, OCOR6, NR6COR7, OCONR6, OR6, SR6, SOR6, SO2R6, SR6N(R7R8), N(R7R8) or Ph; G = monocyclic heteroaryl; X = bond, NH, C1-6 alkyl, alkenyl, alkoxy, alkylthio, or alkylamino, or (CH)J; J = C1-6 alkyl, C3-7 cycloalkyl, Ph, or PhCH2; n = 1-6]. I, or pharmaceutical salts thereof, are useful in the treatment of diseases assocd. with herpes viruses, including human cytomegalovirus (HCMV), herpes simplex viruses (HSV), varicella-zoster virus (VZV), or (no data) Epstein-Barr virus, human herpesviruses-6 and -7, and Kaposi herpesvirus. Approx. 1000 example compds. prepd. by std.

methods are listed, with biol. data for 18 compds. in 4 bioassays. For instance, the N-(4-thioureidophenyl)furan-2-carboxamide deriv. II had an IC50 of 0.4 μg/mL against HCMV wild-type in human foreskin fibroblast cell culture, and 0.5 μg/mL against HSV in an ELISA assay.

IT **273384-69-3P 273384-74-0P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of heterocyclic carboxamide-contg. and phenylenediamine-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 273384-69-3 HCAPLUS
CN Carbamic acid, [4-[(2-fluorobenzoyl)amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 273384-74-0 HCAPLUS
CN Carbamic acid, [4-[[2-(methylsulfinyl)benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **71026-66-9**
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(starting material; prepn. of heterocyclic carboxamide-contg. and phenylenediamine-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 71026-66-9 HCAPLUS
CN Carbamic acid, (4-aminophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **273390-64-0P 273390-92-4P 273390-93-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(target compd.; prepn. of heterocyclic carboxamide-contg. and phenylenediamine-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 273390-64-0 HCAPLUS
CN Benzamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 273390-92-4 HCAPLUS
CN 1,2,3-Thiadiazole-4-carboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 273390-93-5 HCAPLUS
CN 2-Furancarboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L26 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:401808 HCAPLUS
DOCUMENT NUMBER: 133:30588
TITLE: Alpha-methylbenzyl-containing thiourea derivatives containing a phenylenediamine group, useful as inhibitors of herpes viruses
INVENTOR(S): Bloom, Jonathan David; Curran, Kevin Joseph; Digrandi, Martin Joseph; Dushin, Russell George; Lang, Stanley Albert; Norton, Emily Boucher; Ross, Adma Antonia; O'Hara, Bryan Mark
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034260	A2	20000615	WO 1999-US28839	19991206
WO 2000034260	A3	20000908		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,

BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 9916084	A	20010904	BR 1999-16084	19991206
EP 1137645	A2	20011004	EP 1999-963022	19991206
EP 1137645	B1	20040526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002531555	T2	20020924	JP 2000-586707	19991206
ZA 2001004376	A	20020828	ZA 2001-4376	20010528
NO 2001002833	A	20010802	NO 2001-2833	20010608

PRIORITY APPLN. INFO.: US 1998-208902 A 19981209
WO 1999-US28839 W 19991206

OTHER SOURCE(S): MARPAT 133:30588
GI



I



II

AB Title compds. I and related compds. are disclosed [wherein R1-R5 = H, C1-6 alkyl or perhaloalkyl, C2-6 alkenyl or alkynyl, C3-10 (hetero)cycloalkyl, (hetero)aryl, halo, CN, NO2, CO2R6, COR6, OR6, SR6, SOR6, SO2R6, CONR7R8, NR6N(R7R8), N(R7R8), or W-Y-(CH2)n-Z, provided that at least 1 of R1-R5 ≠ H; or R2R3 or R3R4 form 3- to 7-membered heterocycloalkyl or heteroaryl fusion; R6, R7 = H, C1-6 alkyl or perhaloalkyl, or aryl; R8 = H, C1-6 alkyl or perhaloalkyl, C3-10 (hetero)cycloalkyl, (hetero)aryl; or NR7R8 forms 3- to 7-membered heterocycloalkyl; R9-R12 = H, C1-4 alkyl or perhaloalkyl, halo, C1-4 alkoxy, or cyano, or R9R10 or R11R12 = C5-7 aryl fusion; W = O, NR6, or bond; Y = CO, CO2, or bond; Z = C1-4 alkyl, CN, CO2R6, COR6, CONR7R8, OCOR6, NR6COR7, OCONR6, OR6, SR6, SOR6, SO2R6, SR6N(R7R8), N(R7R8) or Ph; G = aryl or fused bicyclic aryl; X = bond, NH, C1-6 alkyl, alkenyl, alkoxy, alkylthio, or alkylamino, or (CH)J; J = C1-6 alkyl, C3-7 cycloalkyl, Ph, or PhCH2; n = 1-6]. I, or pharmaceutical salts thereof, are useful in the treatment of diseases assocd. with herpes viruses, including human cytomegalovirus (HCMV), herpes simplex viruses (HSV), varicella-zoster virus (VZV), or (no data) Epstein-Barr virus, human herpesviruses-6 and -7, and Kaposi herpesvirus. Approx. 1000 example compds. prepd. by std. methods are listed, with biol. data for approx. 320 compds. in 1-4 bioassays. For instance, the [[(phenylethyl)thioureido]phenyl]benzofurancarboxamide deriv. II had an IC50 of 1.3 μg/mL against HCMV wild-type in human foreskin fibroblast cell culture, and 0.10 μg/mL against VZV in an ELISA assay.

IT **273384-69-3P 273384-74-0P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP

(Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of α-methylbenzyl-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 273384-69-3 HCAPLUS
CN Carbamic acid, [4-[(2-fluorobenzoyl)amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 273384-74-0 HCAPLUS
CN Carbamic acid, [4-[[2-(methylsulfinyl)benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 71026-66-9
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(starting material; prepn. of α-methylbenzyl-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 71026-66-9 HCAPLUS
CN Carbamic acid, (4-aminophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 273390-64-0P 273390-92-4P 273390-93-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(target compd.; prepn. of α-methylbenzyl-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 273390-64-0 HCAPLUS
CN Benzamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 273390-92-4 HCAPLUS
CN 1,2,3-Thiadiazole-4-carboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-

imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 273390-93-5 HCAPLUS
CN 2-Furancarboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L26 ANSWER 14 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER:	2000:401806 HCAPLUS
DOCUMENT NUMBER:	133:30733
TITLE:	Heterocyclic carboxamide-containing thiourea derivatives containing a phenylenediamine group, useful as inhibitors of herpes viruses
INVENTOR(S):	Bloom, Jonathan David; Curran, Kevin Joseph; Digrandi, Martin Joseph; Dushin, Russell George; Jones, Thomas Richard; Lang, Stanley Albert; Ross, Adma Antonia; Terefenko, Eugene Anthony; O'Hara, Bryan Mark
PATENT ASSIGNEE(S):	American Home Products Corporation, USA
SOURCE:	PCT Int. Appl., 188 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034258	A2	20000615	WO 1999-US28842	19991206
WO 2000034258	A3	20011129		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 9916046	A	20011002	BR 1999-16046	19991206
EP 1144397	A2	20011017	EP 1999-963023	19991206
EP 1144397	A3	20020911		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

TR 200101664	T2	20020321	TR 2001-200101664		19991206
JP 2002531554	T2	20020924	JP 2000-586705		19991206
ZA 2001004377	A	20021220	ZA 2001-4377		20010528
NO 2001002832	A	20010807	NO 2001-2832		20010608
BG 105581	A	20011231	BG 2001-105581		20010608
PRIORITY APPLN. INFO.:			US 1998-208559	A	19981209
			WO 1999-US28842	W	19991206

OTHER SOURCE(S): MARPAT 133:30733
GI



I



II

AB Title compds. I and related compds. are disclosed [wherein R1-R5 = H, C1-6 alkyl or perhaloalkyl, C2-6 alkenyl or alkynyl, C3-10 (hetero)cycloalkyl, (hetero)aryl, halo, CN, NO2, CO2R6, COR6, OR6, SR6, SOR6, SO2R6, CONR7R8, NR6N(R7R8), N(R7R8), or W-Y-(CH2)n-Z, provided that at least 1 of R1-R5 ≠ H; or R2R3 or R3R4 form 3- to 7-membered heterocycloalkyl or heteroaryl fusion; R6, R7 = H, C1-6 alkyl or perhaloalkyl, or aryl; R8 = H, C1-6 alkyl or perhaloalkyl, C3-10 (hetero)cycloalkyl, (hetero)aryl; or NR7R8 forms 3- to 7-membered heterocycloalkyl; W = O, NR6, or bond; Y = CO, CO2, or bond; Z = C1-4 alkyl, CN, CO2R6, COR6, CONR7R8, OCOR6, NR6COR7, OCONR6, OR6, SR6, SOR6, SO2R6, SR6N(R7R8), N(R7R8) or Ph; G = monocyclic heteroaryl; X = bond, NH, C1-6 alkyl, alkenyl, alkoxy, alkylthio, or alkylamino, or (CH)J; J = C1-6 alkyl, C3-7 cycloalkyl, Ph, or PhCH2; n = 1-6]. I, or pharmaceutical salts thereof, are useful in the treatment of diseases assocd. with herpes viruses, including human cytomegalovirus (HCMV), herpes simplex viruses (HSV), varicella-zoster virus (VZV), or (no data) Epstein-Barr virus, human herpesviruses-6 and -7, and Kaposi herpesvirus. Approx. 1000 example compds. prepd. by std. methods are listed, with biol. data for approx. 350 compds. in 1-4 bioassays. For instance, the thioureidophenylthiadiazolecarboxamide deriv. II had an IC50 of 0.0011 μg/mL against HCMV wild-type in human foreskin fibroblast cell culture.

IT **273384-69-3P 273384-74-0P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of heterocyclic carboxamide-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 273384-69-3 HCAPLUS
CN Carbamic acid, [4-[(2-fluorobenzoyl)amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 273384-74-0 HCAPLUS
CN Carbamic acid, [4-[[2-(methylsulfinyl)benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 71026-66-9
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(starting material; prepn. of heterocyclic carboxamide-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 71026-66-9 HCAPLUS
CN Carbamic acid, (4-aminophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 273390-64-0P 273390-92-4P 273390-93-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(target compd.; prepn. of heterocyclic carboxamide-contg. thiourea derivs. as inhibitors of herpes viruses)

RN 273390-64-0 HCAPLUS
CN Benzamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 273390-92-4 HCAPLUS
CN 1,2,3-Thiadiazole-4-carboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 273390-93-5 HCAPLUS
CN 2-Furancarboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L26 ANSWER 15 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:401786 HCAPLUS
DOCUMENT NUMBER: 133:30587
TITLE: Benzamide-containing aryl thiourea derivatives useful as inhibitors of herpes viruses
INVENTOR(S): Bloom, Jonathan David; Curran, Kevin Joseph; Digrandi, Martin Joseph; Dushin, Russell George; Lang, Stanley Albert; Norton, Emily Boucher; Ross, Adma Antonia; O'Hara, Bryan Mark
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034238	A1	20000615	WO 1999-US28837	19991206
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6166028	A	20001226	US 1999-444782	19991122
US 6197803	B1	20010306	US 1999-447006	19991122
US 6201013	B1	20010313	US 1999-444075	19991122
US 6207715	B1	20010327	US 1999-444897	19991122
US 6255349	B1	20010703	US 1999-444734	19991122
US 6262090	B1	20010717	US 1999-444896	19991122
US 6335350	B1	20020101	US 1999-447005	19991122
BR 9916086	A	20010904	BR 1999-16086	19991206
EP 1137632	A1	20011004	EP 1999-963021	19991206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

TR 200101597	T2	20011022	TR 2001-200101597	19991206
JP 2002531545	T2	20020924	JP 2000-586686	19991206
NZ 512108	A	20030926	NZ 1999-512108	19991206
US 6262082	B1	20010717	US 2000-669483	20000925
US 6271236	B1	20010807	US 2000-669943	20000926
US 6403617	B1	20020611	US 2000-669535	20000926
US 6407123	B1	20020618	US 2000-670180	20000926
US 6426355	B1	20020730	US 2000-671486	20000927
US 6407249	B1	20020618	US 2000-684011	20001229
US 6410571	B1	20020625	US 2000-684773	20001229
US 2002026055	A1	20020228	US 2001-804510	20010312
US 6380243	B2	20020430		
US 2001039348	A1	20011108	US 2001-845428	20010430
US 6462055	B2	20021008		
ZA 2001004144	A	20020821	ZA 2001-4144	20010521
NO 2001002838	A	20010808	NO 2001-2838	20010608
BG 105583	A	20011231	BG 2001-105583	20010608
US 2003036653	A1	20030220	US 2002-99695	20020315
US 6555561	B2	20030429		

PRIORITY APPLN. INFO.:

US 1998-208561	A	19981209
US 1998-228805P	P	19981209
US 1998-228808P	P	19981209
US 1998-228809P	P	19981209
US 1998-150692P	P	19981209
US 1998-150698P	P	19981209
US 1998-155192P	P	19981209
US 1998-155240P	P	19981209
US 1998-208164	A	19981209
US 1998-208540	A	19981209
US 1999-444734	A3	19991122
US 1999-444782	A3	19991122
US 1999-444896	A3	19991122
US 1999-447006	A3	19991122
WO 1999-US28837	W	19991206
US 2000-669535	A3	20000926

OTHER SOURCE(S): MARPAT 133:30587
GI



I

II

AB Title compds. I and related compds. are disclosed [wherein R1-R5 = H, C1-6 alkyl or perhaloalkyl, C2-6 alkenyl or alkynyl, C3-10 (hetero)cycloalkyl, (hetero)aryl, halo, CN, NO2, CO2R6, COR6, OR6, SR6, SOR6, SO2R6, CONR7R8,

NR6N(R7R8), N(R7R8), or W-Y-(CH2)n-Z, provided that at least 1 of R1-R5 ≠ H; or R2R3 or R3R4 form 3- to 7-membered heterocycloalkyl or heteroaryl fusion; R6, R7 = H, C1-6 alkyl or perhaloalkyl, or aryl; R8 = H, C1-6 alkyl or perhaloalkyl, C3-10 (hetero)cycloalkyl, (hetero)aryl; or NR7R8 forms 3- to 7-membered heterocycloalkyl; R9-R12 = H, C1-4 alkyl or perhaloalkyl, halo, C1-4 alkoxy, or cyano, or R9R10 or R11R12 = C5-7 aryl fusion, provided that at least 1 of R9-R12 ≠ H; W = O, NR6, or bond; Y = CO, CO2, or bond; Z = C1-4 alkyl, CN, CO2R6, COR6, CONR7R8, OCOR6, NR6COR7, OCONR6, OR6, SR6, SOR6, SO2R6, SR6N(R7R8), N(R7R8) or Ph; G = aryl or fused bicyclic heteroaryl; X = bond, NH, C1-6 alkyl, alkenyl, alkoxy, alkylthio, or alkylamino, or (CH)J; J = C1-6 alkyl, C3-7 cycloalkyl, Ph, or PhCH2; n = 1-6]. I, or pharmaceutical salts thereof, are useful in the treatment of diseases assocd. with herpes viruses, including human cytomegalovirus (HCMV), herpes simplex viruses (HSV), varicella-zoster virus (VZV), or (no data) Epstein-Barr virus, human herpesviruses-6 and -7, and Kaposi herpesvirus. Approx. 1000 example compds. prepd. by std. methods are listed, with biol. data for approx. 75 compds. in 2-4 bioassays. For instance, the thioureidophenylbenzamide deriv. II had an IC50 of 1.5 μg/mL against HCMV wild-type in human foreskin fibroblast cell culture, and 0.04 μg/mL against HSV in an ELISA assay.

IT **273384-69-3P 273384-74-0P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of benzamide-contg. aryl thiourea derivs. as inhibitors of herpes viruses)

RN 273384-69-3 HCAPLUS
CN Carbamic acid, [4-[(2-fluorobenzoyl)amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 273384-74-0 HCAPLUS
CN Carbamic acid, [4-[[2-(methylsulfinyl)benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **71026-66-9**
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(starting material; prepn. of benzamide-contg. aryl thiourea derivs. as inhibitors of herpes viruses)

RN 71026-66-9 HCAPLUS
CN Carbamic acid, (4-aminophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **273390-64-0P 273390-92-4P 273390-93-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(target compd.; prepn. of benzamide-contg. aryl thiourea derivs. as inhibitors of herpes viruses)

RN 273390-64-0 HCAPLUS
CN Benzamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 273390-92-4 HCAPLUS
CN 1,2,3-Thiadiazole-4-carboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 273390-93-5 HCAPLUS
CN 2-Furancarboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 16 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:401785 HCAPLUS
DOCUMENT NUMBER: 133:30586
TITLE: Acetamide and substituted acetamide-containing aryl thiourea derivatives useful as inhibitors of herpes viruses
INVENTOR(S): Bloom, Jonathan David; Digrandi, Martin Joseph; Dushin, Russell George; Lang, Stanley Albert; O'Hara, Bryan Mark
PATENT ASSIGNEE(S): American Home Products Corporation, USA

SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034237	A2	20000615	WO 1999-US28844	19991206
WO 2000034237	A3	20001123		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1137633	A2	20011004	EP 1999-965132	19991206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916041	A	20011204	BR 1999-16041	19991206
JP 2002531544	T2	20020924	JP 2000-586685	19991206
ZA 2001004142	A	20021025	ZA 2001-4142	20010521
NO 2001002834	A	20010807	NO 2001-2834	20010608

PRIORITY APPLN. INFO.:

US 1998-208316	A	19981209
WO 1999-US28844	W	19991206

OTHER SOURCE(S): MARPAT 133:30586
GI



I



II

AB Title compds. I and related compds. are disclosed [wherein R1-R5 = H, C1-6 alkyl or perhaloalkyl, C2-6 alkenyl or alkynyl, C3-10 (hetero)cycloalkyl, (hetero)aryl, halo, CN, NO2, CO2R6, COR6, OR6, SR6, SOR6, SO2R6, CONR7R8, NR6N(R7R8), N(R7R8), or W-Y-(CH2)n-Z, provided that at least 1 of R1-R5 ≠ H; or R2R3 or R3R4 form 3- to 7-membered heterocycloalkyl or heteroaryl fusion; R6, R7 = H, C1-6 alkyl or perhaloalkyl, or aryl; R8 = H, C1-6 alkyl or perhaloalkyl, C3-10 (hetero)cycloalkyl, (hetero)aryl; or NR7R8 forms 3- to 7-membered heterocycloalkyl; R9-R12 = H, C1-4 alkyl or perhaloalkyl, halo, C1-4 alkoxy, or cyano, or R9R10 or R11R12 = C5-7 aryl

fusion; W = O, NR6, or bond; Y = CO, CO2, or bond; Z = C1-4 alkyl, CN, CO2R6, COR6, CONR7R8, OCOR6, NR6COR7, OCONR6, OR6, SR6, SOR6, SO2R6, SR6N(R7R8), N(R7R8) or Ph; G = C1-6 alkyl; X = bond, NH, C1-6 alkyl, alkenyl, alkoxy, alkylthio, or alkylamino, or (CH)J; J = C1-6 alkyl, C3-7 cycloalkyl, Ph, or PhCH2; n = 1-6]. I, or pharmaceutical salts thereof, are useful in the treatment of diseases assocd. with herpes viruses, including human cytomegalovirus (HCMV), herpes simplex viruses (HSV), varicella-zoster virus (VZV), or (no data) Epstein-Barr virus, human herpesviruses-6 and -7, and Kaposi herpesvirus. Approx. 1000 example compds. prepd. by std. methods are listed, with biol. data for approx. 160 compds. in 4 bioassays. For instance, the thioureidophenylacetamide deriv. II had an IC50 of 0.8 μg/mL against HCMV wild-type in human foreskin fibroblast cell culture, and 2 μg/mL against HSV in an ELISA assay.

IT **273384-69-3P 273384-74-0P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of acetamide-contg. aryl thiourea derivs. as inhibitors of herpes viruses)

RN 273384-69-3 HCAPLUS
CN Carbamic acid, [4-[(2-fluorobenzoyl)amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 273384-74-0 HCAPLUS
CN Carbamic acid, [4-[[2-(methylsulfinyl)benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 71026-66-9
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(starting material; prepn. of acetamide-contg. aryl thiourea derivs. as inhibitors of herpes viruses)

RN 71026-66-9 HCAPLUS
CN Carbamic acid, (4-aminophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **273390-64-0P 273390-92-4P 273390-93-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(target compd.; prepn. of acetamide-contg. aryl thiourea derivs. as inhibitors of herpes viruses)

RN 273390-64-0 HCAPLUS
CN Benzamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 273390-92-4 HCAPLUS
CN 1,2,3-Thiadiazole-4-carboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 273390-93-5 HCAPLUS
CN 2-Furancarboxamide, N-[4-[[[[1-(1,1-dimethylethyl)-1H-imidazol-2-yl]amino]thioxomethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L26 ANSWER 17 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2000:335391 HCAPLUS
DOCUMENT NUMBER: 132:347569
TITLE: Preparation gastrin and cholecystokinin receptor ligands
INVENTOR(S): Kalindjian, Sarkis Barret; Buck, Ildiko Maria; Linney, Ian Duncan; Wright, Paul Trevor; McDonald, Iain Mair; Steel, Katherine Isobel Mary; Hull, Robert Antony David; Roberts, Sonia Patricia; Gaffen, John David; Vinter, Jeremy Gilbert; Walker, Martin Keith; Black, James Whyte; Watt, Gillian Fairfull; Harper, Elaine Anne; Shankley, Nigel Paul; Tozer, Matthew John; Dunstone, David John; Pether, Michael John; Lilley, Elliot James; Sykes, David Andrew; Low, Caroline Minli Rachel; Griffin, Eric Peter; Wright, Laurence
PATENT ASSIGNEE(S): James Black Foundation Limited, UK
SOURCE: PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027823	A1	20000518	WO 1999-GB3733	19991109
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346108	AA	20000518	CA 1999-2346108	19991109
BR 9915194	A	20010807	BR 1999-15194	19991109
EP 1178969	A1	20020213	EP 1999-954196	19991109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002529455	T2	20020910	JP 2000-581003	19991109
NO 2001002288	A	20010702	NO 2001-2288	20010509
US 6479531	B1	20021112	US 2001-831385	20010802
PRIORITY APPLN. INFO.:			GB 1998-24536 A	19981109
			GB 1999-16786 A	19990716
			WO 1999-GB3733 W	19991109

OTHER SOURCE(S): MARPAT 132:347569
GI



AB Title compds. (I) [wherein X and Y = independently N, N(R5), CH, S, or O; n = 1-4; Z = (NR7)aCO(NR8)b, CONR7CH2CONR8, CO2, CH2CH2, CH=CH, CH2N(R8), or a bond; a and b = independently 0 or 1; Q = R9V (un)substituted phenyl(alkyl); V = CONHSO2Ph, SO2NHCOPh, CH2OH, etc.; R1 = H or (halo)hydrocarbyl where ≤ 3 C atoms may be replaced by N, O, and/or S atoms; R2 = H, Me, Et, Pr, or OH; R3 = H, Me, Et, or Pr; or 2 adjacent R3 groups form a carbocyclic ring when n > 1; or R2 and R3 on the same C atom together = :O ; R4 = (halo)hydrocarbyl where ≤ 2 C atoms may be replaced by N, O, and/or S atoms; R5 = H, Me, Et, Pr, benzyl, OH, or carboxymethyl (esters); R7 and R8 = independently H, Me, Et, Pr, or benzyl; R9 = CH2, CH2CH2, or (un)substituted phenylmethylene; or R8 and R9, together with the adjacent N, form a substituted piperidine or pyrrolidine] and their pharmaceutically acceptable salts were prepd. Examples include syntheses and biol. data for 314 compds. Thus, 2-adamantan-1-ylmethyl-5-phenyl-1H-pyrrole-3-carboxylic acid (3-step prepn. given) was coupled with 5-aminoisophthalic acid dibenzyl ester (45%), followed by deprotection (98%) to give II. II had pKi of 6.72 for binding at the CCKB mouse cortical membranes and pKb of 6.33 for gastrin antagonist activity.

IT **269071-04-7P 269071-45-6P**

RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; RACT (Reactant or reagent)
(intermediate; prepn. gastrin and cholecystokinin receptor ligands)

RN 269071-04-7 HCAPLUS

CN Benzoic acid, 3-[[[[2-(2-methylphenyl)-5-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-1H-imidazol-4-yl]amino]carbonyl]amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 269071-45-6 HCAPLUS

CN Benzoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-5-[[[2-(2-methylphenyl)-5-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-1H-imidazol-4-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT **269072-17-5**

RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(reactant; prepn. gastrin and cholecystokinin receptor ligands)

RN 269072-17-5 HCAPLUS

CN Benzoic acid, 5-amino-2-[[(1,1-dimethylethoxy)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT **269068-26-0P 269073-03-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(target compd.; prepn. gastrin and cholecystokinin receptor ligands)

RN 269068-26-0 HCAPLUS
CN Benzoic acid, 3-[[[[2-(2-methylphenyl)-5-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-1H-imidazol-4-yl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 269073-03-2 HCAPLUS
CN D-Glucitol, 1-deoxy-1-(methylamino)-, 3-[[[[2-(2-methylphenyl)-5-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-1H-imidazol-4-yl]amino]carbonyl]amino]benzoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 269068-26-0
CMF C30 H34 N4 O3



CM 2

CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 18 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:425745 HCAPLUS
DOCUMENT NUMBER: 131:87909
TITLE: Inhibition of p38 kinase activity using substituted heterocyclic ureas
INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932111	A1	19990701	WO 1998-US26080	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315720	AA	19990701	CA 1998-2315720	19981222
AU 9919971	A1	19990712	AU 1999-19971	19981222
AU 739642	B2	20011018		
EP 1041982	A1	20001011	EP 1998-964709	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526223	T2	20011218	JP 2000-525102	19981222

PRIORITY APPLN. INFO.: US 1997-995750 A 19971222
WO 1998-US26080 W 19981222

OTHER SOURCE(S): MARPAT 131:87909
GI



II

AB A method for treatment of p38-mediated disease other than cancer comprises administration of ANHCONHB [I; A = substituted isoxazolyl, pyrazolyl, thienyl, furyl; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl contg. ≥1 5-6 membered arom. structure contg. 0-4 N, O, or S atoms]. Reaction of 4-(4-pyridinylthio)aniline with 3-tert-butyl-5-isoxazolyl isocyanate in toluene gave title compd. II. In an in vitro p38 kinase assay, I displayed IC50 values of 1-10 μM.

IT **135680-03-4P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of substituted heterocyclic ureas for treatment of p38 kinase-mediated diseases other than cancer)

RN 135680-03-4 HCAPLUS
CN Carbamic acid, [4-[(4-aminophenyl)methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **229002-05-5P 229003-23-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(prepn. of substituted heterocyclic ureas for treatment of p38 kinase-mediated diseases other than cancer)

RN 229002-05-5 HCAPLUS
CN Urea, N-[4-[(4-aminophenyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229003-23-0 HCAPLUS
CN 1H-Pyrazole-1-acetic acid, 5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-3-(1,1-dimethylethyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT 227623-22-5P 227623-23-6P 229001-93-8P
229001-95-0P 229001-97-2P 229001-98-3P
229002-00-0P 229002-01-1P 229002-02-2P
229002-03-3P 229002-04-4P 229002-06-6P
229002-07-7P 229002-08-8P 229002-09-9P
229002-10-2P 229002-11-3P 229002-12-4P
229002-13-5P 229002-14-6P 229002-15-7P
229002-16-8P 229002-17-9P 229002-18-0P
229002-19-1P 229002-20-4P 229002-21-5P
229002-22-6P 229002-24-8P 229002-25-9P
229002-26-0P 229002-27-1P 229002-28-2P
229002-87-3P 229002-97-5P 229002-98-6P
229002-99-7P 229155-38-8P 229155-39-9P
229155-40-2P 229155-41-3P 229155-42-4P
229155-43-5P 229155-44-6P 229155-45-7P
229155-46-8P 229155-47-9P 229155-48-0P
229155-49-1P 229155-50-4P 229155-51-5P
229155-52-6P 229155-53-7P 229155-54-8P
229155-55-9P 229155-56-0P 229155-69-5P
229155-70-8P 229155-71-9P 229155-81-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of substituted heterocyclic ureas for treatment of p38 kinase-mediated diseases other than cancer)

RN 227623-22-5 HCAPLUS
CN Carbamic acid, (2,3-dichlorophenyl)-, 3-[[5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 227623-23-6 HCAPLUS
CN Urea, N-(2,3-dichlorophenyl)-N'-[3-(1,1-dimethylethyl)-1-[(3-hydroxyphenyl)methyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229001-93-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-95-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[2-(4-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 229001-97-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-pyridinylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-98-3 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-(4-pyridinylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 229002-00-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(phenylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 229002-01-1 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4-hydroxyphenyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-02-2 HCAPLUS
CN Urea, N-[4-[(4-butoxyphenyl)thio]phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-03-3 HCAPLUS
CN Butanamide, N-[4-[[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 229002-04-4 HCAPLUS
CN Carbamic acid, [4-[[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 229002-06-6 HCAPLUS
CN Acetamide, N-[4-[[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-07-7 HCAPLUS
CN Butanoic acid, 4-[[4-[[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 229002-08-8 HCAPLUS
CN Propanamide, N-[4-[[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-09-9 HCAPLUS
CN Urea, N-[4-(4-aminophenoxy)phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-10-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-

pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229002-11-3 HCAPLUS
CN Carbamic acid, [4-[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenoxy]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 229002-12-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4-pyridinylmethyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-13-5 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4-pyridinylthio)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-14-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 229002-15-7 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 229002-16-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229002-17-9 HCAPLUS
CN Urea, N-[3-(2-benzothiazolyloxy)phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-18-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4-phenyl-2-thiazolyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-19-1 HCAPLUS
CN Urea, N-[4-(2-benzothiazolylthio)-3-(trifluoromethyl)phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-20-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[4-(1,1-dimethylethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-21-5 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[4-[(trifluoromethyl)thio]phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-22-6 HCAPLUS
CN Urea, N-[1,1'-biphenyl]-3-yl-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-24-8 HCAPLUS
CN Butanamide, N-[4-[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenoxy]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 229002-25-9 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4-propoxyphenyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-26-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 229002-27-1 HCAPLUS
CN Urea, N-[1-(2-cyanoethyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 229002-28-2 HCAPLUS
CN 1H-Pyrazole-1-carboxylic acid, 3-(1,1-dimethylethyl)-5-[[[[4-[3-[(methylamino)carbonyl]phenoxy]phenyl]amino]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 229002-87-3 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[[(9H-fluoren-2-ylamino)carbonyl]amino]-1-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 229002-97-5 HCAPLUS
CN Urea, N-(2,3-dichlorophenyl)-N'-[3-(1,1-dimethylethyl)-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-98-6 HCAPLUS
CN 1H-Pyrazole-1-acetic acid, 5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 229002-99-7 HCAPLUS
CN 1H-Pyrazole-1-acetamide, 5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 229155-38-8 HCAPLUS
CN Urea, N-[4-[(4,5-dihydro-4-phenyl-5-thioxo-1,3,4-thiadiazol-2-yl)thio]phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229155-39-9 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4,5-diphenyl-2-thiazolyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 229155-40-2 HCAPLUS
CN Urea, N-[4-([1,1'-biphenyl]-4-yloxy)-3-(trifluoromethyl)phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229155-41-3 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[4-(phenylmethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 229155-42-4 HCAPLUS
CN Urea, N,N''-(methylenedi-4,1-phenylene)bis[N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229155-43-5 HCAPLUS
CN Urea, N,N''-(oxydi-4,1-phenylene)bis[N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229155-44-6 HCAPLUS
CN Propanamide, N-[4-[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 229155-45-7 HCAPLUS
CN Acetamide, N-[4-[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 229155-46-8 HCAPLUS
CN Carbamic acid, [4-[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenoxy]phenyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 229155-47-9 HCAPLUS
CN Urea, N-(2,3-dichlorophenyl)-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229155-48-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 229155-49-1 HCAPLUS
CN Urea, N-(3,5-dibromophenyl)-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229155-50-4 HCAPLUS
CN Benzoic acid, 4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-, butyl ester (9CI) (CA INDEX NAME)



RN 229155-51-5 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-pyridinylthio)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 229155-52-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[2-(4-pyridazinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 229155-53-7 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-pyridinylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 229155-54-8 HCAPLUS

CN Urea, N-(2,3-dichlorophenyl)-N'-[3-(1,1-dimethylethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229155-55-9 HCAPLUS
CN Urea, N-[1-(2-cyanoethyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-(2,3-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 229155-56-0 HCAPLUS
CN Urea, N-[1-cyclohexyl-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 229155-69-5 HCAPLUS
CN Benzamide, 4-[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenoxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 229155-70-8 HCAPLUS
CN Benzamide, 4-[[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]thio]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 229155-71-9 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[[3-[[[(1-methyl-3-phenyl-1H-pyrazol-5-yl)amino]carbonyl]amino]phenyl]thio]- (9CI) (CA INDEX NAME)



RN 229155-81-1 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-5-[4-[[[(1-methyl-3-phenyl-1H-pyrazol-5-yl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



IT **229003-22-9**
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(reactant; prepn. of substituted heterocyclic ureas for treatment of p38 kinase-mediated diseases other than cancer)
RN 229003-22-9 HCAPLUS
CN Carbamic acid, (2,3-dichlorophenyl)-, 2-[5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 19 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:425740 HCAPLUS
DOCUMENT NUMBER: 131:73648
TITLE: Inhibition of raf kinase using substituted heterocyclic ureas
INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932106	A1	19990701	WO 1998-US26078	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315717	AA	19990701	CA 1998-2315717	19981222
AU 9921989	A1	19990712	AU 1999-21989	19981222
EP 1047418	A1	20001102	EP 1998-965981	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200002618	T2	20010420	TR 2000-200002618	19981222
JP 2001526220	T2	20011218	JP 2000-525097	19981222
BR 9814374	A	20020514	BR 1998-14374	19981222
NO 2000003232	A	20000821	NO 2000-3232	20000621
BG 104597	A	20010228	BG 2000-104597	20000712

PRIORITY APPLN. INFO.: US 1997-996343 A 19971222
WO 1998-US26078 W 19981222

OTHER SOURCE(S): MARPAT 131:73648
GI



II

AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl contg. ≥1 5-6 membered arom. structure contg. 0-4 N, O, or S atoms]. Reaction of 4-phenyloxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temp. for 2 days gave title

compd. II. In an in vitro raf kinase assay, I displayed IC50 values of 1-10 μM.

IT **135680-03-4P**

RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)

RN 135680-03-4 HCAPLUS

CN Carbamic acid, [4-[(4-aminophenyl)methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **229002-05-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(prepn. of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)

RN 229002-05-5 HCAPLUS

CN Urea, N-[4-[(4-aminophenyl)methyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



IT **229001-93-8P** **229001-94-9P** **229001-95-0P**
229001-96-1P **229001-97-2P** **229001-98-3P**
229001-99-4P **229002-00-0P** **229002-01-1P**
229002-02-2P **229002-03-3P** **229002-04-4P**
229002-06-6P **229002-07-7P** **229002-08-8P**
229002-09-9P **229002-10-2P** **229002-11-3P**
229002-12-4P **229002-13-5P** **229002-14-6P**
229002-15-7P **229002-16-8P** **229002-17-9P**
229002-18-0P **229002-19-1P** **229002-20-4P**
229002-21-5P **229002-22-6P** **229002-23-7P**
229002-24-8P **229002-25-9P** **229002-26-0P**
229002-27-1P **229002-28-2P** **229002-85-1P**
229002-86-2P **229002-87-3P** **229002-97-5P**
229002-98-6P **229002-99-7P** **229003-04-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)

RN 229001-93-8 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-94-9 HCAPLUS
CN Benzamide, 5-[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenoxy]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 229001-95-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[2-(4-pyridinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 229001-96-1 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4-methoxyphenyl)methylamino]phenyl]- (9CI) (CA INDEX NAME)



RN 229001-97-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-pyridinylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-98-3 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-(4-pyridinylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 229001-99-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[[2-(trifluoromethyl)-4-pyridinyl]thio]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-00-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(phenylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 229002-01-1 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4-hydroxyphenyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-02-2 HCAPLUS
CN Urea, N-[4-[(4-butoxyphenyl)thio]phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-03-3 HCAPLUS

CN Butanamide, N-[4-[[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 229002-04-4 HCAPLUS

CN Carbamic acid, [4-[[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 229002-06-6 HCAPLUS

CN Acetamide, N-[4-[[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-07-7 HCAPLUS

CN Butanoic acid, 4-[[4-[[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 229002-08-8 HCAPLUS

CN Propanamide, N-[4-[[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-09-9 HCAPLUS
CN Urea, N-[4-(4-aminophenoxy)phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-10-2 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229002-11-3 HCAPLUS
CN Carbamic acid, [4-[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenoxy]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 229002-12-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4-pyridinylmethyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-13-5 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4-pyridinylthio)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-14-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 229002-15-7 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 229002-16-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-(4-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229002-17-9 HCAPLUS
CN Urea, N-[3-(2-benzothiazolyloxy)phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-18-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4-phenyl-

2-thiazolyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-19-1 HCAPLUS
CN Urea, N-[4-(2-benzothiazolylthio)-3-(trifluoromethyl)phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-20-4 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[4-(1,1-dimethylethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-21-5 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[4-[(trifluoromethyl)thio]phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-22-6 HCAPLUS
CN Urea, N-[1,1'-biphenyl]-3-yl-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-23-7 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[3-

(phenylmethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-24-8 HCAPLUS
CN Butanamide, N-[4-[4-[[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]phenoxy]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 229002-25-9 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[4-[(4-propoxyphenyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 229002-26-0 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 229002-27-1 HCAPLUS
CN Urea, N-[1-(2-cyanoethyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 229002-28-2 HCAPLUS
CN 1H-Pyrazole-1-carboxylic acid, 3-(1,1-dimethylethyl)-5-[[[[4-[3-

[(methylamino)carbonyl]phenoxy]phenyl]amino]carbonyl]amino]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 229002-85-1 HCAPLUS
CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[4-(6-quinolinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 229002-86-2 HCAPLUS
CN 2-Pyridinecarboxamide, N-methyl-4-[4-[[[(1-methyl-3-phenyl-1H-pyrazol-5-yl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 229002-87-3 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[[(9H-fluoren-2-ylamino)carbonyl]amino]-1-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 229002-97-5 HCAPLUS
CN Urea, N-(2,3-dichlorophenyl)-N'-[3-(1,1-dimethylethyl)-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 229002-98-6 HCAPLUS
CN 1H-Pyrazole-1-acetic acid, 5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 229002-99-7 HCAPLUS
CN 1H-Pyrazole-1-acetamide, 5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 229003-04-7 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



IT 229003-22-9 229003-25-2
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(reactant; prepn. of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)

RN 229003-22-9 HCAPLUS
CN Carbamic acid, (2,3-dichlorophenyl)-, 2-[5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]ethyl ester (9CI) (CA INDEX NAME)



RN 229003-25-2 HCAPLUS
CN Carbamic acid, [4-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 20 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1998:402427 HCAPLUS
DOCUMENT NUMBER: 129:81759
TITLE: Preparation and formulation of benzodiazepine derivatives as gastrin and cholecystokinin antagonists
INVENTOR(S): Shinozaki, Katsuo; Yoneta, Tomoyuki; Murata, Masakazu; Miura, Naoyoshi; Maeda, Kiyoto
PATENT ASSIGNEE(S): Zeria Pharmaceutical Co., Ltd., Japan; Shinozaki, Katsuo;; Yoneta, Tomoyuki;; Murata Masakazu;; Miura, Naoyoshi;; Maeda, Kiyoto;
SOURCE: PCT Int. Appl., 432 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825911	A1	19980618	WO 1997-JP4534	19971210
W: AU, CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9854100	A1	19980703	AU 1998-54100	19971210
AU 721081	B2	20000622		
EP 945445	A1	19990929	EP 1997-947872	19971210

EP 945445	B1	20030903			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
CN 1246850	A	20000308	CN 1997-181599		19971210
CN 1130351	B	20031210			
AT 248823	E	20030915	AT 1997-947872		19971210
PT 945445	T	20040130	PT 1997-947872		19971210
ES 2206754	T3	20040516	ES 1997-947872		19971210
US 6239131	B1	20010529	US 1999-319249		19990608
KR 2000057506	A	20000915	KR 1999-705193		19990610
PRIORITY APPLN. INFO.:			JP 1996-344498	A	19961210
			JP 1997-156132	A	19970530
			WO 1997-JP4534	W	19971210

OTHER SOURCE(S): MARPAT 129:81759

GI



I



II

AB The title compds. I [R1 represents hydrogen, lower alkyl, lower alkoxy or halogeno; R2 and R3 may be the same or different and each represents hydrogen, alkenyl, alkyl, Ph, acyl, etc.; and R4 and R5 may be the same or different and each represents hydrogen, alkyl, carboxyl, etc.; Ar = arom. heterocycle, etc.; n = 0 or 2] are prepd. The compds. have an excellent gastrin and/or CCK-B receptor antagonism and are useful as remedies for gastric ulcer and gastrointestinal movement disorder. In an in vitro test for CCK-B receptor antagonism, the title compd. (+)-II showed the Ki value of 1.16 nM. (+)-II at 1 mg/kg intraduodenally gave 81% inhibition of stomach acid secretion induced by pentagastrin 15 μg/kg/h in rats.

IT **209219-48-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(prepn. of benzodiazepine derivs. as gastrin and cholecystokinin antagonists)

RN 209219-48-7 HCAPLUS

CN Urea, N-[5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-2,3,4,5-tetrahydro-2-oxo-1H-1,5-benzodiazepin-3-yl]-N'-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



IT **19962-06-2**
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(prepn. of benzodiazepine derivs. as gastrin and cholecystokinin antagonists)
RN 19962-06-2 HCAPLUS
CN Carbamic acid, (3-hydroxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **209222-94-6P 209222-95-7P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzodiazepine derivs. as gastrin and cholecystokinin antagonists)
RN 209222-94-6 HCAPLUS
CN Propanoic acid, 2-[3-[[(1,1-dimethylethoxy)carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 209222-95-7 HCAPLUS
CN Propanoic acid, 2-[3-[[(1,1-dimethylethoxy)carbonyl]amino]phenoxy]-2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 21 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1995:709095 HCAPLUS
DOCUMENT NUMBER: 123:218414

TITLE: Imidazoles and antiarteriosclerotics containing the imidazoles
INVENTOR(S): Kumazawa, Toshiaki; Harakawa, Hiroyuki; Fukui, Hiromi; Shirokura, Shiro; Ooishi, Eiko; Yamada, Koji
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07133224	A2	19950523	JP 1993-280961	19931110

PRIORITY APPLN. INFO.: JP 1993-280961 19931110
OTHER SOURCE(S): MARPAT 123:218414
GI



I

AB Antiarteriosclerotics contain imidazoles I [X, Y = CH, N; Z = single bond, CH2; R1, R2, R3 = H, halo, lower alkyl, OH, lower alkoxy, carboxy, lower alkoxycarbonyl, NH2, mono- or di-lower alkyl-substituted amino, carbamoyl, mono- or di-lower alkyl-substituted carbamoyl, CF3; R4, R5, R6 = H, halo, lower alkyl, lower alkoxy; R7 = H, lower alkyl, lower alkyl-(un)substituted cycloalkyl] or their pharmacol. acceptable salts as active ingredients. N-[1-(2-chlorophenyl)-2-benzimidazolyl]-N'-(2,6-diisopropylphenyl)urea (II) (2.3 g) was prepd. by treatment of 1.5 g 2-amino-1-(2-chlorophenyl)benzimidazole and 1.46 mL 2,6-diisopropylphenyl isocyanate. II (at 10-7M) inhibited acyl CoA:cholesterol acyltransferase by 85%. II showed min. LD of >100 mg/kg i.p. in mice. A formulation example of tablets is given.

IT **168120-11-4P 168120-12-5P 168120-13-6P**
168120-16-9P 168120-18-1P 168120-21-6P
168120-32-9P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(antiarteriosclerotics contg. imidazoles)

RN 168120-11-4 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-phenyl-1H-benzimidazol-2-yl)-(9CI) (CA INDEX NAME)



RN 168120-12-5 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(2-chlorophenyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-13-6 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(3-chlorophenyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-16-9 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(2-methylphenyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-18-1 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-[2-(dimethylamino)phenyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-21-6 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(2,6-dichlorophenyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-32-9 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[3-(2-chlorophenyl)-3H-imidazo[4,5-b]pyridin-2-yl]- (9CI) (CA INDEX NAME)



IT **168120-19-2P 168120-27-2P 168120-30-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(antiarteriosclerotics contg. imidazoles)

RN 168120-19-2 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(2-methoxyphenyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-27-2 HCAPLUS
CN Benzoic acid, 3-[2-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-1H-benzimidazol-1-yl]-4-chloro-, methyl ester (9CI) (CA INDEX NAME)



RN 168120-30-7 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(2-chlorophenyl)-6-methoxy-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



IT **168120-14-7P 168120-15-8P 168120-17-0P**
168120-20-5P 168120-22-7P 168120-23-8P
168120-24-9P 168120-25-0P 168120-26-1P
168120-28-3P 168120-29-4P 168120-31-8P
168120-33-0P 168120-34-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(antiarteriosclerotics contg. imidazoles)

RN 168120-14-7 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(4-chlorophenyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-15-8 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(2-bromophenyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-17-0 HCAPLUS

CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-[2-(trifluoromethyl)phenyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-20-5 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(2-hydroxyphenyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-22-7 HCAPLUS
CN Urea, N-[1-(2-chlorophenyl)-1H-benzimidazol-2-yl]-N'-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 168120-23-8 HCAPLUS
CN Urea, N-[1-(2-chlorophenyl)-1H-benzimidazol-2-yl]-N'-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 168120-24-9 HCAPLUS
CN Urea, N-[1-(2,6-dichlorophenyl)-1H-benzimidazol-2-yl]-N'-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 168120-25-0 HCAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N'-[1-(2,6-dichlorophenyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-26-1 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-[2-chloro-4-(dimethylamino)phenyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-28-3 HCAPLUS
CN Benzoic acid, 3-[2-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-1H-benzimidazol-1-yl]-4-chloro- (9CI) (CA INDEX NAME)



RN 168120-29-4 HCAPLUS
CN 1H-Benzimidazole-6-carboxylic acid, 2-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-1-(2-chlorophenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 168120-31-8 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(2-chlorophenyl)-6-hydroxy-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-33-0 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(4-chloro-3-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 168120-34-1 HCAPLUS
CN Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[1-(4-methyl-2-pyridinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



IT 138046-81-8
RL: **RCT (Reactant)**; RACT (Reactant or reagent)
(reaction in prepn. of imidazoles as antiarteriosclerotics)
RN 138046-81-8 HCAPLUS
CN Carbamic acid, (2,4,6-trimethylphenyl)-, phenyl ester (9CI) (CA INDEX NAME)




```
=> file caold
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                      106.97     692.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                          ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -14.55     -16.53

FILE 'CAOLD' ENTERED AT 10:15:20 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> d his

     (FILE 'HOME' ENTERED AT 09:29:11 ON 24 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 09:29:19 ON 24 JUN 2004

     FILE 'CASREACT' ENTERED AT 09:43:31 ON 24 JUN 2004
L1                STRUCTURE UPLOADED
L2              0 S L1
L3              0 S L1 FULL
L4                STRUCTURE UPLOADED
L5              0 S L4
L6              3 S L4 FULL

     FILE 'REGISTRY' ENTERED AT 09:47:01 ON 24 JUN 2004
L7                STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 09:48:17 ON 24 JUN 2004
L8             50 S L7
L9           1575 S L7 FULL

     FILE 'HCAPLUS' ENTERED AT 09:48:40 ON 24 JUN 2004
L10           225 S L9/PREP
```

```
     FILE 'REGISTRY' ENTERED AT 09:48:47 ON 24 JUN 2004
L11                STRUCTURE UPLOADED
L12            50 S L11
L13                STRUCTURE UPLOADED
L14            49 S L13
L15                STRUCTURE UPLOADED
L16             8 S L15
L17                STRUCTURE UPLOADED
L18            50 S L17
                   E INDANYL/CN
L19             1 S E7
                   E BENZOFURAN/CN
L20             1 S E3
                   E INDENYL/CN
L21             1 S E3
L22                STRUCTURE UPLOADED
L23            50 S L22
L24         65845 S L22 FULL

     FILE 'HCAPLUS' ENTERED AT 10:10:57 ON 24 JUN 2004
L25          6528 S L24/RCT
L26            21 S L25 AND L10

     FILE 'REGISTRY' ENTERED AT 10:13:07 ON 24 JUN 2004
L27                STRUCTURE UPLOADED
L28            50 S L27

     FILE 'HCAPLUS' ENTERED AT 10:13:28 ON 24 JUN 2004
L29             0 S L26 AND TAN, Z?/AU
L30             0 S L26 AND SONG, J?/AU

     FILE 'CAOLD' ENTERED AT 10:15:20 ON 24 JUN 2004

=> s l24 and l9
TOO MANY TERMS FOR FILE CROSSOVER IN L24
There are limits on the size of an answer set being crossed over from
one file to another.  Enter HELP CROSSOVER at an arrow prompt (=>)
for specific information.

=> s l9
L31           14 L9

=> s l24
TOO MANY TERMS FOR FILE CROSSOVER IN L24
There are limits on the size of an answer set being crossed over from
one file to another.  Enter HELP CROSSOVER at an arrow prompt (=>)
for specific information.

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     2.10     694.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -16.53

FILE 'REGISTRY' ENTERED AT 10:18:16 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

```
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 JUN 2004  HIGHEST RN 698346-19-9
DICTIONARY FILE UPDATES:  23 JUN 2004  HIGHEST RN 698346-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> e 2-amino pyrazole/cn
E1            1      2-AMINO CYCLIC AMP/CN
E2            1      2-AMINO MUSK XYLENE/CN
E3            0 --> 2-AMINO PYRAZOLE/CN
E4            1      2-AMINO((METHOXYCARBONYL)THIOUREIDO)BENZENE/CN
E5            1      2-AMINO(1)BENZOTHIENO(2,3-B)(1)BENZOTHIOPYRAN-11-ONE/CN
E6            1      2-AMINO(HYDRAZONO)METHYL-1,10-PHENANTHROLINE/CN
E7            1      2-AMINO(PENTAFLUOROETHYL)BENZENE HYDROCHLORIDE/CN
E8            1      2-AMINO-(3-(TERT-BUTYLOXYCARBONYL)PIPERIDIN-1-YL)BENZENE/CN
E9            1      2-AMINO-.ALPHA.,.ALPHA.,.ALPHA.,5,6-PENTAFLUOROACETOPHENONE/
                     CN
E10           1      2-AMINO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-P-TOLUENESULFONAMI
                     DE/CN
E11           1      2-AMINO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-P-TOLUENESULFONYL
                     CHLORIDE/CN
E12           1      2-AMINO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUOROTOLUENE/CN

=> e amino pyrazole/cn
E1            1      AMINO PEGA RESIN/CN
E2            1      AMINO POLYOL AMINE OXIDASE/CN
E3            0 --> AMINO PYRAZOLE/CN
E4            1      AMINO RADICAL/CN
E5            1      AMINO RADICAL (NH2)/CN
E6            1      AMINO SEPHAROSE 6 FAST FLOW/CN
E7            1      AMINO SILOXANES AND SILICONES/CN
E8            1      AMINO TRANSFERASE (STREPTOMYCES COELICOLOR STRAIN A3(2) GENE
                      SCF55.27)/CN
E9            1      AMINO TRANSFERASE (THERMUS THERMOPHILUS STRAIN HB8)/CN
E10           1      AMINO VALERIC ACID/CN
E11           1      AMINO(((2-NITROPHENYL)METHYL)AMINO)METHANE-1-THIONE/CN
E12           1      AMINO((3,4-DICHLOROPHENYL)AMINO)METHANE-1-THIONE/CN

=>
L32      STRUCTURE UPLOADED

=> d l32
L32 HAS NO ANSWERS
L32                STR
 Ak ß O M1 X 8
Page 1-A
```



Page 1-B



Page 2-B
VAR G1=6/7/8/2
NODE ATTRIBUTES:
HCOUNT IS M1 AT 7
NSPEC IS C AT 1
NSPEC IS C AT 2
NSPEC IS C AT 3
NSPEC IS C AT 4
NSPEC IS C AT 5
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 1 2 3 6 7 8
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE

=> s 132
SAMPLE SEARCH INITIATED 10:23:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 16360 TO ITERATE

6.1% PROCESSED 1000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 319545 TO 334855
PROJECTED ANSWERS: 79883 TO 87643

L33 50 SEA SSS SAM L32

=> s l32 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:24:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 327382 TO ITERATE

```
100.0% PROCESSED  327382 ITERATIONS                    89725 ANSWERS
SEARCH TIME: 00.00.04

L34         89725 SEA SSS FUL L32

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             159.20     853.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00     -16.53

FILE 'HCAPLUS' ENTERED AT 10:24:24 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 24 Jun 2004  VOL 140 ISS 26
FILE LAST UPDATED: 23 Jun 2004  (20040623/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> s l34/rct
        117519 L34
       2633407 RCT/RL
L35      36779 L34/RCT
                 (L34 (L) RCT/RL)

=> d his

     (FILE 'HOME' ENTERED AT 09:29:11 ON 24 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 09:29:19 ON 24 JUN 2004

     FILE 'CASREACT' ENTERED AT 09:43:31 ON 24 JUN 2004
L1                STRUCTURE UPLOADED
L2              0 S L1
L3              0 S L1 FULL
L4                STRUCTURE UPLOADED
L5              0 S L4
L6              3 S L4 FULL

     FILE 'REGISTRY' ENTERED AT 09:47:01 ON 24 JUN 2004
L7                STRUCTURE UPLOADED
```

```
     FILE 'REGISTRY' ENTERED AT 09:48:17 ON 24 JUN 2004
L8             50 S L7
L9           1575 S L7 FULL

     FILE 'HCAPLUS' ENTERED AT 09:48:40 ON 24 JUN 2004
L10           225 S L9/PREP

     FILE 'REGISTRY' ENTERED AT 09:48:47 ON 24 JUN 2004
L11                STRUCTURE UPLOADED
L12            50 S L11
L13                STRUCTURE UPLOADED
L14            49 S L13
L15                STRUCTURE UPLOADED
L16             8 S L15
L17                STRUCTURE UPLOADED
L18            50 S L17
                   E INDANYL/CN
L19             1 S E7
                   E BENZOFURAN/CN
L20             1 S E3
                   E INDENYL/CN
L21             1 S E3
L22                STRUCTURE UPLOADED
L23            50 S L22
L24         65845 S L22 FULL

     FILE 'HCAPLUS' ENTERED AT 10:10:57 ON 24 JUN 2004
L25          6528 S L24/RCT
L26            21 S L25 AND L10

     FILE 'REGISTRY' ENTERED AT 10:13:07 ON 24 JUN 2004
L27                STRUCTURE UPLOADED
L28            50 S L27

     FILE 'HCAPLUS' ENTERED AT 10:13:28 ON 24 JUN 2004
L29             0 S L26 AND TAN, Z?/AU
L30             0 S L26 AND SONG, J?/AU

     FILE 'CAOLD' ENTERED AT 10:15:20 ON 24 JUN 2004
L31            14 S L9

     FILE 'REGISTRY' ENTERED AT 10:18:16 ON 24 JUN 2004
                   E 2-AMINO PYRAZOLE/CN
                   E AMINO PYRAZOLE/CN
L32                STRUCTURE UPLOADED
L33            50 S L32
L34         89725 S L32 FULL

     FILE 'HCAPLUS' ENTERED AT 10:24:24 ON 24 JUN 2004
L35         36779 S L34/RCT

=> d his

     (FILE 'HOME' ENTERED AT 09:29:11 ON 24 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 09:29:19 ON 24 JUN 2004

     FILE 'CASREACT' ENTERED AT 09:43:31 ON 24 JUN 2004
L1                 STRUCTURE UPLOADED
```

```
L2              0 S L1
L3              0 S L1 FULL
L4                STRUCTURE UPLOADED
L5              0 S L4
L6              3 S L4 FULL

     FILE 'REGISTRY' ENTERED AT 09:47:01 ON 24 JUN 2004
L7                STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 09:48:17 ON 24 JUN 2004
L8             50 S L7
L9           1575 S L7 FULL

     FILE 'HCAPLUS' ENTERED AT 09:48:40 ON 24 JUN 2004
L10           225 S L9/PREP

     FILE 'REGISTRY' ENTERED AT 09:48:47 ON 24 JUN 2004
L11               STRUCTURE UPLOADED
L12            50 S L11
L13               STRUCTURE UPLOADED
L14            49 S L13
L15               STRUCTURE UPLOADED
L16             8 S L15
L17               STRUCTURE UPLOADED
L18            50 S L17
                  E INDANYL/CN
L19             1 S E7
                  E BENZOFURAN/CN
L20             1 S E3
                  E INDENYL/CN
L21             1 S E3
L22               STRUCTURE UPLOADED
L23            50 S L22
L24         65845 S L22 FULL

     FILE 'HCAPLUS' ENTERED AT 10:10:57 ON 24 JUN 2004
L25          6528 S L24/RCT
L26            21 S L25 AND L10

     FILE 'REGISTRY' ENTERED AT 10:13:07 ON 24 JUN 2004
L27               STRUCTURE UPLOADED
L28            50 S L27

     FILE 'HCAPLUS' ENTERED AT 10:13:28 ON 24 JUN 2004
L29             0 S L26 AND TAN, Z?/AU
L30             0 S L26 AND SONG, J?/AU

     FILE 'CAOLD' ENTERED AT 10:15:20 ON 24 JUN 2004
L31            14 S L9

     FILE 'REGISTRY' ENTERED AT 10:18:16 ON 24 JUN 2004
                  E 2-AMINO PYRAZOLE/CN
                  E AMINO PYRAZOLE/CN
L32               STRUCTURE UPLOADED
L33            50 S L32
L34         89725 S L32 FULL

     FILE 'HCAPLUS' ENTERED AT 10:24:24 ON 24 JUN 2004
L35         36779 S L34/RCT
```

```
=> d his

     (FILE 'HOME' ENTERED AT 09:29:11 ON 24 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 09:29:19 ON 24 JUN 2004

     FILE 'CASREACT' ENTERED AT 09:43:31 ON 24 JUN 2004
L1                STRUCTURE UPLOADED
L2              0 S L1
L3              0 S L1 FULL
L4                STRUCTURE UPLOADED
L5              0 S L4
L6              3 S L4 FULL

     FILE 'REGISTRY' ENTERED AT 09:47:01 ON 24 JUN 2004
L7                STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 09:48:17 ON 24 JUN 2004
L8             50 S L7
L9           1575 S L7 FULL

     FILE 'HCAPLUS' ENTERED AT 09:48:40 ON 24 JUN 2004
L10           225 S L9/PREP

     FILE 'REGISTRY' ENTERED AT 09:48:47 ON 24 JUN 2004
L11               STRUCTURE UPLOADED
L12            50 S L11
L13               STRUCTURE UPLOADED
L14            49 S L13
L15               STRUCTURE UPLOADED
L16             8 S L15
L17               STRUCTURE UPLOADED
L18            50 S L17
                  E INDANYL/CN
L19             1 S E7
                  E BENZOFURAN/CN
L20             1 S E3
                  E INDENYL/CN
L21             1 S E3
L22               STRUCTURE UPLOADED
L23            50 S L22
L24         65845 S L22 FULL

     FILE 'HCAPLUS' ENTERED AT 10:10:57 ON 24 JUN 2004
L25          6528 S L24/RCT
L26            21 S L25 AND L10

     FILE 'REGISTRY' ENTERED AT 10:13:07 ON 24 JUN 2004
L27               STRUCTURE UPLOADED
L28            50 S L27

     FILE 'HCAPLUS' ENTERED AT 10:13:28 ON 24 JUN 2004
L29             0 S L26 AND TAN, Z?/AU
L30             0 S L26 AND SONG, J?/AU

     FILE 'CAOLD' ENTERED AT 10:15:20 ON 24 JUN 2004
L31            14 S L9

     FILE 'REGISTRY' ENTERED AT 10:18:16 ON 24 JUN 2004
               E 2-AMINO PYRAZOLE/CN
```

```
                E AMINO PYRAZOLE/CN
L32             STRUCTURE UPLOADED
L33          50 S L32
L34       89725 S L32 FULL

     FILE 'HCAPLUS' ENTERED AT 10:24:24 ON 24 JUN 2004
L35       36779 S L34/RCT

=> s l35 and l26
L36           1 L35 AND L26

=> d l36, ibib abs, 1

L36  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

Full Text | Citing References

```
ACCESSION NUMBER:          2000:666713  HCAPLUS
DOCUMENT NUMBER:           133:252426
TITLE:                     Preparation of aromatic heterocyclic ureas as
                           antiinflammatory agents
INVENTOR(S):               Betageri, Rajashehar; Breitfelder, Steffen; Cirillo,
                           Pier F.; Gilmore, Thomas A.; Hickey, Eugene R.;
                           Kirrane, Thomas M.; Moriak, Monica H.; Moss, Neil;
                           Patel, Usha R.; Proudfoot, John R.; Regan, John R.;
                           Sharma, Rajiv; Sun, Sanxing; Swinamer, Alan D.;
                           Takahashi, Hidenori
PATENT ASSIGNEE(S):        Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE:                    PCT Int. Appl., 282 pp.
                           CODEN: PIXXD2
DOCUMENT TYPE:             Patent
LANGUAGE:                  English
FAMILY ACC. NUM. COUNT:    3
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000055139	A2	20000921	WO 2000-US3865	20000216
WO 2000055139	A3	20010426		
W: AE, AU, BG, BR, BY, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, VN, YU, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1165516	A2	20020102	EP 2000-907295	20000216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008922	A	20020115	BR 2000-8922	20000216
TR 200102817	T2	20020521	TR 2001-200102817	20000216
JP 2002539198	T2	20021119	JP 2000-605569	20000216
EE 200100483	A	20021216	EE 2001-483	20000216
NZ 514711	A	20040227	NZ 2000-514711	20000216
AU 771273	B2	20040318	AU 2000-28817	20000216
BG 105880	A	20020531	BG 2001-105880	20010905
ZA 2001007446	A	20020910	ZA 2001-7446	20010910
HR 2001000665	A1	20030630	HR 2001-665	20010910
NO 2001004412	A	20010911	NO 2001-4412	20010911
US 2002055507	A1	20020509	US 2001-962709	20010925
US 6660732	B2	20031209		
US 2002082256	A1	20020627	US 2001-962057	20010925
US 6656933	B2	20031202		

US 2003225077	A1	20031204	US 2003-424613		20030428
US 2004019038	A1	20040129	US 2003-624289		20030721
PRIORITY APPLN. INFO.:			US 1999-124148P	P	19990312
			US 1999-165867P	P	19991116
			US 2000-505582	A3	20000216
			WO 2000-US3865	W	20000216
			US 2001-962057	A1	20010925
			US 2001-962709	A3	20010925

OTHER SOURCE(S): MARPAT 133:252426
GI



I



II

AB The title compds. (I) [wherein Ar1 = (un)substituted pyrrole, pyrrolidine, pyrazole, imidazole, oxazole, thiazole, furan, or thiophene; Ar2 = (un)substituted Ph, (tetrahydro)naphthyl, (tetrahydro)quinoline, (tetrahydro)isoquinoline, benzimidazole, benzofuran, indanyl, indenyl, or indole; W = O or S; X = (un)substituted cycloalkyl, cycloalkenyl, Ph, furan, thiophene, pyrrole, imidazolyl, pyridine, pyrimidine, (dihydro)pyridinone, (dihydro)maleimide, piperidine, piperazine, or pyrazine; Y = a bond or (un)substituted satd. or unsatd. alkyl optionally interrupted by O, NH, S(O), SO2, or S; Z = (un)substituted Ph, pyridine, pyrimidine, pyridazine, imidazole, (tetrahydro)furan, thiophene, (tetrahydro)pyran, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxane, (thio)morpholine (sulfoxide), piperidine, cyclohexanone, pentamethylene sulfoxide, etc.] were prepd. for the treatment of diseases or pathol. conditions involving inflammation, such as chronic inflammatory diseases. Thus, coupling 2-cyclohexenone with 4-bromo-1-naphthylamine in the presence of Pd(PPh3)2Cl2, DPPP, and NaHCO3 in DMF, followed by conversion of the amine to an isocyanate using ClCOCl and immediate addn. of 1-(4-methylphenyl)-3-tert-butyl-1H-pyrazol-5-amine, gave the urea II. In a cytokine prodn. inhibition assay, preferred compds. of the invention showed IC50 < 10 μM against TNF-α in lipopolysaccharide stimulated THF cells.

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.70	870.13

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY     SESSION
CA SUBSCRIBER PRICE                                  -0.69      -17.22

FILE 'CAOLD' ENTERED AT 10:28:13 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> d his

     (FILE 'HOME' ENTERED AT 09:29:11 ON 24 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 09:29:19 ON 24 JUN 2004

     FILE 'CASREACT' ENTERED AT 09:43:31 ON 24 JUN 2004
L1                STRUCTURE UPLOADED
L2              0 S L1
L3              0 S L1 FULL
L4                STRUCTURE UPLOADED
L5              0 S L4
L6              3 S L4 FULL

     FILE 'REGISTRY' ENTERED AT 09:47:01 ON 24 JUN 2004
L7                STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 09:48:17 ON 24 JUN 2004
L8             50 S L7
L9           1575 S L7 FULL

     FILE 'HCAPLUS' ENTERED AT 09:48:40 ON 24 JUN 2004
L10           225 S L9/PREP

     FILE 'REGISTRY' ENTERED AT 09:48:47 ON 24 JUN 2004
L11               STRUCTURE UPLOADED
L12            50 S L11
L13               STRUCTURE UPLOADED
L14            49 S L13
L15               STRUCTURE UPLOADED
L16             8 S L15
L17               STRUCTURE UPLOADED
L18            50 S L17
                  E INDANYL/CN
L19             1 S E7
                  E BENZOFURAN/CN
L20             1 S E3
```

```
                E INDENYL/CN
L21             1 S E3
L22               STRUCTURE UPLOADED
L23            50 S L22
L24         65845 S L22 FULL

     FILE 'HCAPLUS' ENTERED AT 10:10:57 ON 24 JUN 2004
L25          6528 S L24/RCT
L26            21 S L25 AND L10

     FILE 'REGISTRY' ENTERED AT 10:13:07 ON 24 JUN 2004
L27               STRUCTURE UPLOADED
L28            50 S L27

     FILE 'HCAPLUS' ENTERED AT 10:13:28 ON 24 JUN 2004
L29             0 S L26 AND TAN, Z?/AU
L30             0 S L26 AND SONG, J?/AU

     FILE 'CAOLD' ENTERED AT 10:15:20 ON 24 JUN 2004
L31            14 S L9

     FILE 'REGISTRY' ENTERED AT 10:18:16 ON 24 JUN 2004
                E 2-AMINO PYRAZOLE/CN
                E AMINO PYRAZOLE/CN
L32             STRUCTURE UPLOADED
L33            50 S L32
L34         89725 S L32 FULL

     FILE 'HCAPLUS' ENTERED AT 10:24:24 ON 24 JUN 2004
L35         36779 S L34/RCT
L36             1 S L35 AND L26

     FILE 'CAOLD' ENTERED AT 10:28:13 ON 24 JUN 2004

=> s l34 and l9
TOO MANY TERMS FOR FILE CROSSOVER IN L34
There are limits on the size of an answer set being crossed over from
one file to another.  Enter HELP CROSSOVER at an arrow prompt (=>)
for specific information.

=> s l9 and l34
TOO MANY TERMS FOR FILE CROSSOVER IN L34
There are limits on the size of an answer set being crossed over from
one file to another.  Enter HELP CROSSOVER at an arrow prompt (=>)
for specific information.

=> s l31 and base
          9375 BASE
          6467 BASES
         15700 BASE
                (BASE OR BASES)
L37             0 L31 AND BASE

=> file reg
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                             5.51     875.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                              ENTRY    SESSION
```

CA SUBSCRIBER PRICE 0.00 -17.22

FILE 'REGISTRY' ENTERED AT 10:33:49 ON 24 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2004 HIGHEST RN 698346-19-9
DICTIONARY FILE UPDATES: 23 JUN 2004 HIGHEST RN 698346-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L38 STRUCTURE UPLOADED

=> d 138
L38 HAS NO ANSWERS
L38 STR

Ak 8 0 M1 X 9
Page 1-A



Page 1-B

Page 2-B
VAR G1=7/8/9/2
NODE ATTRIBUTES:
HCOUNT IS M1 AT 8

```
NSPEC   IS C       AT   1
NSPEC   IS C       AT   2
NSPEC   IS C       AT   3
NSPEC   IS C       AT   4
NSPEC   IS C       AT   5
NSPEC   IS C       AT   6
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   1  2  3  7  8  9
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   9

STEREO ATTRIBUTES: NONE
```

```
=> s l38
SAMPLE SEARCH INITIATED 10:35:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  55513 TO ITERATE

  1.8% PROCESSED    1000 ITERATIONS                                  50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      EXCEEDS 1000000
PROJECTED ANSWERS:         EXCEEDS  584795

L39          50 SEA SSS SAM L38

=> e silicon/cn
E1           1     SILICOMOLYBDOVANADIC ACID (H6MO10SIV2O40)/CN
E2           1     SILICOMONAZITE/CN
E3           1 --> SILICON/CN
E4           1     SILICON (DIPHOSPHATE)/CN
E5           1     SILICON (SI(3+))/CN
E6           1     SILICON (SI10+) CLUSTER ION/CN
E7           1     SILICON (SI11+) CLUSTER ION/CN
E8           1     SILICON (SI12+) CLUSTER ION/CN
E9           1     SILICON (SI13+) CLUSTER ION/CN
E10          1     SILICON (SI14+) CLUSTER ION/CN
E11          1     SILICON (SI15+) CLUSTER ION/CN
E12          1     SILICON (SI16+) CLUSTER ION/CN

=> s e3
L40          1 SILICON/CN

=> d l3
L3 HAS NO ANSWERS
L1               STR
L3            0 SEA FILE=CASREACT SSS FUL L1 (     0 REACTIONS)


=> d his

     (FILE 'HOME' ENTERED AT 09:29:11 ON 24 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 09:29:19 ON 24 JUN 2004
```

```
     FILE 'CASREACT' ENTERED AT 09:43:31 ON 24 JUN 2004
L1                STRUCTURE UPLOADED
L2              0 S L1
L3              0 S L1 FULL
L4                STRUCTURE UPLOADED
L5              0 S L4
L6              3 S L4 FULL

     FILE 'REGISTRY' ENTERED AT 09:47:01 ON 24 JUN 2004
L7                STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 09:48:17 ON 24 JUN 2004
L8             50 S L7
L9           1575 S L7 FULL

     FILE 'HCAPLUS' ENTERED AT 09:48:40 ON 24 JUN 2004
L10           225 S L9/PREP

     FILE 'REGISTRY' ENTERED AT 09:48:47 ON 24 JUN 2004
L11               STRUCTURE UPLOADED
L12            50 S L11
L13               STRUCTURE UPLOADED
L14            49 S L13
L15               STRUCTURE UPLOADED
L16             8 S L15
L17               STRUCTURE UPLOADED
L18            50 S L17
                  E INDANYL/CN
L19             1 S E7
                  E BENZOFURAN/CN
L20             1 S E3
                  E INDENYL/CN
L21             1 S E3
L22               STRUCTURE UPLOADED
L23            50 S L22
L24         65845 S L22 FULL

     FILE 'HCAPLUS' ENTERED AT 10:10:57 ON 24 JUN 2004
L25          6528 S L24/RCT
L26            21 S L25 AND L10

     FILE 'REGISTRY' ENTERED AT 10:13:07 ON 24 JUN 2004
L27               STRUCTURE UPLOADED
L28            50 S L27

     FILE 'HCAPLUS' ENTERED AT 10:13:28 ON 24 JUN 2004
L29             0 S L26 AND TAN, Z?/AU
L30             0 S L26 AND SONG, J?/AU

     FILE 'CAOLD' ENTERED AT 10:15:20 ON 24 JUN 2004
L31            14 S L9

     FILE 'REGISTRY' ENTERED AT 10:18:16 ON 24 JUN 2004
                  E 2-AMINO PYRAZOLE/CN
                  E AMINO PYRAZOLE/CN
L32               STRUCTURE UPLOADED
L33            50 S L32
L34         89725 S L32 FULL
```

```
     FILE 'HCAPLUS' ENTERED AT 10:24:24 ON 24 JUN 2004
L35        36779 S L34/RCT
L36            1 S L35 AND L26

     FILE 'CAOLD' ENTERED AT 10:28:13 ON 24 JUN 2004
L37            0 S L31 AND BASE

     FILE 'REGISTRY' ENTERED AT 10:33:49 ON 24 JUN 2004
L38              STRUCTURE UPLOADED
L39           50 S L38
                 E SILICON/CN
L40            1 S E3

=>
```

Patent Assignment Abstract of Title

Total Assignments: 1

Application #: 10074895 **Filing Dt:** 02/12/2002 **Patent #:** NONE **Issue Dt:**

PCT #: NONE **Publication #:** US20020123631 **Pub Dt:** 09/05/

Inventors: Zhulin Tan, Jinhua J. Song

Title: Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents

Assignment: 1

Reel/Frame: 012594/0147 **Received:** 02/26/2002 **Recorded:** 02/12/2002 **Mailed:** 04/17/2002 **Pag**

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: TAN, ZHULIN **Exec Dt:** 01/17/2002

SONG, JINHUA J. **Exec Dt:** 01/17/2002

Assignee: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
P.O. BOX 368
900 RIDGEBURY ROAD
RIDGEFIELD, CONNECTICUT 06877

Correspondent: BOEHRINGER INGELHEIM CORPORATION
ROBERT P. RAYMOND
900 RIDGEBURY ROAD
P.O. BOX 368
RIDGEFIELD, CT 06877-0368

Search Results as of: 6/20/2004 10:47:05 P.M.